EXHIBIT A

CURRICULUM VITAE

Stephen Dewhurst, Ph.D.

Personal Information

Name: Stephen Dewhurst
SSN: [redacted]
Work Address: Department of Microbiology and Immunology
University of Rochester Medical Center, Box 672
601 Elmwood Avenue. Rochester, NY 14642
Home Address: [redacted]
Rochester, NY 14607
Tel.: Work: (585) 275-3216
Email: stephen_dewhurst@urmc.rochester.edu
WWW: http://www.urmc.rochester.edu/smd/mbi/faculty/dewhurst.htm
Date of Birth: [redacted]
Place of Birth: Manchester, United Kingdom
Citizenship: U.S. citizen (naturalized, March 2002)

Education

1981-1984	B.S., Cellular Pathology, Bristol University, Bristol, England.
1984-1987	Ph.D., Microbiology, University of Nebraska Med. Center, Omaha, NE.

Postdoctoral Training

1987-1988	Postdoctoral Fellow, Department of Medicine and Pediatrics, Columbia University, New York, NY.
1988-1990	Postdoctoral Fellow, Department of Cancer Biology, Harvard School of Public Health, Boston, MA.

Current Appointments

2001-present	Professor, Department of Microbiology and Immunology, URSMD, Rochester, NY.
2013-present	Vice Dean for Research, URSMD
2023-present	Vice President for Research, UR

Table of Contents/Index

Prior Appointments 3
Honors & Awards 3
A. Educational Contributions - Lecturing, Mentoring 4
B. Professional Service - Intramural, Extramural 17
C. Research Activities - Current Awards; Prior Awards 30
D. Presentations 49
E. Publications 55
Review Articles & Book Chapters 69
F. Patents 74

Prior Appointments

1990-1995	Assistant Professor, Department of Microbiology and Immunology, University of Rochester School of Medicine & Dentistry (URSMD), Rochester, NY.
1992-1995	Assistant Professor, Cancer Center, URSMD
1995-1998	Associate Professor, Department of Microbiology and Immunology, and Cancer Center, URSMD
1998-2001	Associate Professor with unlimited tenure, Department of Microbiology and Immunology, and Associate Professor, Cancer Center, URSMD
2000-present	Affiliate member, Center for Vaccine Biology & Immunology, URSMD
2001-present	Professor, Department of Microbiology and Immunology, URSMD
2002-2017	Dean's Professor of Microbiology and Immunology, URSMD
2005-2009	Associate Chair, Department of Microbiology and Immunology, URSMD
2007-2009	Senior Associate Dean for Basic Research, URSMD
2009-2021	Chair, Department of Microbiology and Immunology, URSMD
2013-2021	Associate Vice President for Health Sciences Research, UR
2013-present	Vice Dean for Research, URSMD
2020-2023	Albert and Phyllis Ritterson Professor, Dept. of Microbiology and Immunology, URSMD
2021-2023	Interim Vice President for Research, UR
2023-present	Vice President for Research, UR

Honors and Awards

1988-1991:	AIDS Research Scholar, American Foundation for AIDS Research
1994-1999:	Research Career Development Award, NIH/NIAID
1995:	Friend of Education Award, Rochester City School District, Rochester NY
1996:	Graduate Student Society (GSS) Faculty Teaching Award, URSMD
2002-19:	Dean's Professor of Microbiology and Immunology, URSMD
2002:	Graduate Alumni Award for Excellence in Graduate Education, URSMD
2003:	University Dean's Award for Meritorious Service in Ph.D. Defenses, UR
2003-04:	Chair, NIH/NIAID AIDSRRC Charter Study Section
2004-08:	Member, NIH Recombinant DNA Advisory Committee (RAC)
2008:	William H. Riker University Award for Excellence in Graduate Education, UR *(this is the UR's highest award for graduate education and mentoring)*
2008-14:	Member, NIH OBA Working Group on Biosafety (advisory to the RAC)
2015:	Outstanding Training Program Director, URSMD
2018:	Best Presentation award (Joint winner), URBEST Retreat, URSMD
2020-2023:	Albert & Phyllis Ritterson Professor of Microbiology & Immunology, URSMD
2021:	Graduate Student Society (GSS) Student Advocacy Award, URSMD

A. Educational Contributions

Past 5 years, and selected earlier activities

1. Medical Students

Lecturing, Other Group-Based Teaching

2007-2015: REMS (Rochester Early Medical Scholars) program: annual seminar on "HIV Vaccines"

2007-pres: Co-presenter (with Eric Caine and now Ben Lee), annual "Research as a Human Enterprise" seminar series for medical students in the Academic Research Track

2007-2019: Member, Faculty Organizing Committee, Process of Discovery (POD) Course (*4th year medical school course).*

2009-2022: Annual Lecturer, Process of Discovery (POD) Course: Translational Research and Technology Commercialization (presentation on "*Bringing Bench Science to the Bedside*")

2010-2012: Lecturer, Host Defense Course. 3 lectures (2010); 4 lectures (2011, 2012)

2. Graduate and M.D/Ph.D. Students

Lecturing, Other Group-Based Teaching

1991-2007: Lecturer, General Virology (MBI 456). **Course Director** from 2001-2004.

1991-2011: Presenter, Virology Research in Progress (MBI 588) and Advanced Topics in Virology (MBI 589) seminar courses. Course director (MBI 588): 1997-2004; **Course Director** (MBI 589): 1994, 1996.

2001-2004: Syllabus co-developer, Facilitator: Effective Scientific Communication (MBI 509). Course was ultimately discontinued.

2000-pres.: Lecturer, Ethics & Professional Integrity Course (IND 501). *1 lecture on plagiarism and scientific misconduct annually, plus development of associated case studies (2000-2017). From 2017 onwards, I have delivered a presentation on Scientific Rigor.*

2009: Panel Member/Presenter, "*Best Practices from UR Award Winning Teachers*". Part of the Provost's orientation for new faculty. Feb 2009.

2011: PREP Trainee Enrichment Seminar Series. Presentation on "*How to Get a Mentor*"

2011: Diversity Seminar Series (Organizers: Vice Provost Vivian Lewis and Associate Dean Linda Chaudron). Presentation on "*Mentors and Mentees*"

2011: Lecturer, Drug Discovery Course (MBI 593): "*An Overview of Technology Commercialization and How New Drugs Are Discovered*"

2011: **CoDirector** and CoDeveloper, with Carrie Dykes, Biology of HIV/AIDS course. *This course was run on a trial basis, but ultimately terminated*.

2012: Copresenter (w. Bob Freeman), special graduate student seminar on "*CV preparation*".

2012-2018: PREP Trainee Enrichment Seminar Series. Annual presentation on "*Preparation of personal statements and CVs*".

2012: Scientific Reasoning in Medicine course (for M.D./Ph.D. trainees). Presentation on translational research ("*A novel microbicide target for reduction of HIV transmission*").

2012: GSS Seminar. Presentation on "*At the Podium: Techniques to Perfect Your Talk*" (discussion of how to give a compelling 10-minute research presentation)

2016-pres.: Annual Presenter, IND 494: Leadership and Management for Scientists (presentation on "*Managing People*").

2017: Invited Presenter, IND 436 CTSI Seminar Series: "*Self Confidence*"

2018-pres: Annual Presenter, Virology Research in Progress (MBI 588)

2018: Pecha Kucha presentation ("*What my Students Have Taught Me*"), URBEST Retreat (*selected as the joint-best presentation at the retreat, by the attendees*)

Coordination/Organization of Educational Activities

2009-2021: Organizer, Annual UR World AIDS Day Scientific Symposium & Poster Sessions

2009-2012: **Initiated** and organized, Annual Research Retreat for the Department of Microbiology & Immunology and the Immunology, Microbiology and Virology Graduate Program. This retreat includes all students in the graduate program (PhD and MS), plus all department and center faculty and research staff. *Subsequently, this has been organized by other members of the department*

2011: **Initiated** and coordinated new 3+2 BS/MS program in Microbiology & Immunology. *This program is now being led by Jacques Robert*

2012-2021: **Initiated** and co-coordinated new Master of Science in Technical Entrepreneurship and Management (TEAM) in Biomanufacturing and Therapeutic Development (TEAM-BMTD). *This program was approved by New York State in 2015; the program was launched in fall 2016 with an initial class of 6 full-time domestic students. As of 2021, the program is on hiatus due to the closure of the URMC's cGMP Cell Therapy Manufacturing Facility (CTMF)*

2017-2020: **Initiated** and organized, Annual Core Faculty Retreat for the Department of Microbiology & Immunology. *This retreat is for faculty members in the "core" department and focuses on the departmental missions of research and teaching, with emphasis on forward-looking strategic planning.*

Predoctoral (Ph.D. Program) Trainees (Previous – Complete List)

[#]: African American/Black or Hispanic/Latino(a). These individuals are highlighted here because of the historic exclusion of these identities from the U.S. biomedical research enterprise.

1992-1996: Suryaram Gummuluru. *Current position: Professor and Vice Chair, Dept. of Microbiology & Immunology, Boston University, Boston, MA.*

1993-1997: Carrie Dykes. *Current position: Director of Research Services, Clinical and Translational Sciences Institute (CTSI), URSMD*

1993-1997: Hongyu Deng. *Current position: Professor (Principle Investigator), Key Laboratory of Infection and Immunity, Chinese Academy of Sciences, Beijing, China*

1995-1999: Shekema Hodge-Chambers#. Dr. Hodge received the 1999 Melville A. Hare Award for the most outstanding Ph.D. thesis in the Department of Microbiology and Immunology. *Current Position: Senior Director and Department Head, Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA*

1997-2002: Peter Hocknell. *Current Position: Senior Director, Analytical Development & Quality Control, Leap Therapeutics, Boston, MA.*

1998-2002: Julie Richards Gunzler (M.D., Ph.D.). *Current Position: Pediatrician, Pediatricenter, Cleveland, OH*

1999-2002: Joseph F. Sanchez# *Current Position: Site Learning and Development Director, Merck, West Point, PA*

2002-2003: Matt Renda (comentor with B. Bambara, following the relocation of Dr. Vicente Planelles [his original advisor] to the University of Utah). *Current Position: Director, Medical Writing Operations, Alexion Pharmaceuticals Inc., Greater NYC Area*

1999-2004: Servio Ramirez# *Current Position: Professor, Pathology & Lab Medicine, Temple University, Philadelphia, PA.*

1999-2004: Ramothea Webster (M.D., Ph.D.)# *Current Position: Flight Surgeon (Major), U.S. Air Force*

2002-2005: Zhu (Julia) Zhen. *Current Position: Director, Strategy and Business Development (Cell and Gene Therapy), Thermo Fisher Scientific*

2001-2006: Casey Maguire. *Current Position: Associate Professor of Neurology, Harvard Medical School/Massachusetts General Hospital, Boston MA.*

2001-2006: Heather Lankes (M.P.H., Ph.D.). *Current Position: NRG Oncology Biospecimen Bank-Columbus, The Research Institute at Nationwide Children's Hospital, Columbus, OH*

2001-2006: Kathlyn Santos#. Ms. Santos received the 2007 Melville A. Hare Award for the most outstanding Ph.D. thesis in the Department of Microbiology and Immunology. *Current Position: Assistant Program Manager, Johns Hopkins University Applied Physics Laboratory, Johns Hopkins University, Baltimore, MD*

2003-2006: Christine Zanghi (M.D., Ph.D.). *Current Position: Center Emergency Medical Associates, State College, PA*

2002-2007: Ramil Sapinoro# *Current Position: Associate Professor, Pharmaceutical Sciences, St. John Fisher College, Rochester, NY.*

2003-2007: Cindy Duke (M.D., Ph.D.)# *Current Position: Medical Director and Founding Physician, Nevada Fertility Clinic, Las Vegas, NV; Clinical Assistant Professor, UNLV School of Medicine*

2005-2009: Ketna Volcy# *Current Position: Medical Writer, Radius Health Inc., Boston*

2008-2011: Joanna S.T. Olsen (M.D., Ph.D.) *Current Position: Anesthesiologist, Bend Anesthesiology Group, Bend, OR*

2005-2011: Cristina Capella# *Current Position: Principle Research Scientist (Virologist III), Batelle Biomedical Research Institute, West Jefferson, OH*

2006-2012: Vincent Fong (M.D., Ph.D) *Current Position: Assistant Professor of Clinical, Endocrinology, University of Cincinnati*

2008-2013: Jharon Silva# (M.D./Ph.D). *Current position: Emergency Medicine Physician, Hospital of Central Connecticut, West Hartford, CT*

2009-2013: David Easterhoff. *Current position: Associate Scientific Director, Moderna, Cambridge, MA*

2007-2013: William Domm. *Current position: Senior Research Scientist, Bausch + Lomb, Rochester, NY*

2010-2015: Lauren (Fischer) Brooks. *Current position: Assistant Professor, Clinical Laboratory Sciences, Nazareth College, Rochester, NY*

2013-2016: Andrew Cox (M.D./Ph.D.). Andy received the 2016 Melville A. Hare Award for Excellence in Graduate Research for the most outstanding Ph.D. thesis in the Department of Microbiology and Immunology - as well as the 2016 Wallace O. Fenn Award for Excellence in Research (the highest student research award at the UR School of Medicine & Dentistry). Andy was also the first student to be awarded an independent UR Ventures grant and is co-inventor on our influenza vaccine patent. *Current position: Clinical Fellow, Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center*

2012-2017: Matthew Brewer. *Current Position: Postdoctoral Fellow, University of Rochester*

2015-2019: Andrew Smith (M.D./Ph.D. program). *Current Position: Medical School, University of Rochester*

2016-2020: Rachel Warren. Co-Advisor with Michael O'Reilly, PhD. *Current position: Research Fellow, Mayo Clinic, Rochester, MN*

2019-2020: Emily Weber. Co-mentor with Sanjay Maggirwar. Emily joined our lab when Sanjay left to become Chair of Micro at George Washington University in 2019. Current position: Assistant Professor, North Carolina Wesleyan University, Rocky Mount, NC

2019-2020: Sydney Simpson. Co-mentor with Sanjay Maggirwar. Sydney joined our lab when Sanjay left to become Chair of Micro at George Washington University. *Current position: Senior Scientist, QuidelOrtho Corp. (formerly Ortho Clinical Diagnostics), Rochester, NY.*

2018-2023: Raven Osborn#. Co-mentor with Juilee Thakar (IIMP program). *Current position: Advisor, Translational Pathology Bioinformatics, Eli Lilly and Company, Indianapolis, IN.*

.

Post-Bacc. (PREP Program) Trainees (Previous – Complete List)

All are African American/Black or Hispanic/Latino(a), unless otherwise indicated. These individuals are highlighted here because of the historic exclusion of these identities from the U.S. biomedical research enterprise.

2003-2004: Angela Burgess. Subsequently completed her M.D./Ph.D. at New York Medical College. *Current position: Maternal Medical Director and Vice Chair of Diversity, Equity and Inclusion; Assistant Professor; University of Texas Health Science Center at Houston (UTHealth)*

2003-2006: Sol Rodriguez-Colon. Awarded Du Vigneaud Prize for Best Oral/Poster Research Presentation, annual summer research symposium, URMC, 2005. Subsequently completed her M.P.H. at Penn State. *Current position: Project Manager, Cancer Institute, Penn State College of Medicine.*

2006-2007: Jharon Silva. Subsequently completed his M.D./Ph.D. at UR. *Current position: See under Ph.D. trainees (previous)*

2007-2009: Odaelys (Walwyn) Pollard. Subsequently completed her Ph.D. at New York Medical College. *Current position: Science Education Program & Training Manager, The Rockefeller University*

2010-2011: Zalika Nilsbeth. Subsequently completed her M.D. at Meharry Medical School. *Current position: Family Medicine clinician, Miller County Hospital, Savannah, GA*

2011-2012: Luis Lebron. *Current position: Deceased*

2012-2013: Krisia Montalvo. Subsequently completed her B.S.N. and M.S.M. at Northeastern University. *Current position: Nurse Practitioner, Beth Israel Deaconess Medical Center, Boston*

2014-2015: Claudia Isabel Gonzalez. Subsequently completed her M.S. at the University of Florida. *Current position: Adjunct Professor, Miami Dade College, Miami, FL*

2015: Beedamariam Kessaw. Subsequently transferred to lab of Toru Takimoto, while remaining in the PREP program. *Current position: Unknown*

2017-2018: Lauren Roberts. *Current position: Ph.D. student, University of Florida, Gainesville, FL*

Mentored Predoctoral (M.S. Program) Trainees (Previous – Complete List)

[#]*: African American/Black or Hispanic/Latino(a). These individuals are highlighted here because of the historic exclusion of these identities from the U.S. biomedical research enterprise.*

1995-1997: Duane Hassane (M.S.). *Current position: Vice President of Cardio-Oncology, Tempus Labs, New York, NY*

1996-2000: Renee (Norton) Kirk (M.S.) *[co-advisor with M. Caserta]. Current position: Senior Research Scientist, Vaccinex, Rochester, NY*

1997-1999: Sam Wang (M.S.) *[co-advisor with J. Yang]. Current position: Unknown*

1997-1998:	Jennifer Seils (M.S.). *Current position: Veeva Vault System Administrator, EQRx, Cambridge, MA*
2000-2003:	Xinhong Zheng (M.S.). *Current position: Unknown*
2000-2001:	Casey Maguire (M.S.). *Current position: See under Ph.D. trainees (previous)*
2006-2007:	William Domm (M.S.). *Current position: See under Ph.D. trainees (previous)*
2005-2008:	Andrea S. Marino (M.S.). [co-advisor with Mary Caserta]. *Current position: Laboratory Technician, University of Rochester*
2012-2015:	Colleen O'Dell (M.S.). *Current position: Lab Manager (Paige Lawrence Lab), University of Rochester*
2012-2014:	Kun Hyoe (Jules) Rhoo (M.S.). Subsequently completed her Ph.D. at UR. *Current position: Senior Scientist, AstraZeneca, Gaithersburg, MD*
2013-2014:	Kristen Frantzen (M.S.). *Current position: Executive Assistant to CEO, Monarque Health & Wellness, Ashland, OR*
2017-2018:	Sandra Ortega# (M.S.). *Current position: Nurse, New Mexico*
2019-2021:	Taylor Jones. *Current position: Ph.D. student, IMV Program, University of Rochester*

Predoctoral (Ph.D. Program) Trainees (Current)

#: African American/Black or Hispanic/Latino(a). These individuals are highlighted here because of the historic exclusion of these identities from the U.S. biomedical research enterprise.

2019-present:	Justin Leach
2021-present:	Sebastian Bosch#
2021-present:	Alaa Ahmed

Post-Bacc. (PREP Program) Trainees (Current)

None active

Mentored Predoctoral (M.S. Program) Trainees (Current)

None active

Graduation Student Rotations

Not listed, for reasons of space

Membership of Student Supervisory or Examination Committees

Excludes students under my supervision; past 10 years only

Ph.D. Thesis Committees (past)

#: member of under-represented racial/ethnic minority group (Black or Latinx)

2008-2012:	Emily Desmet, Dept. of Microbiol and Immunol (Mentor: T. Takimoto)

2008-2012:	Matt Kennedy, Dept. of Microbiol and Immunol (Mentor: B. Kim)
2008-2012:	Danielle Alcéna#, Dept. of Microbiol and Immunol (Mentor: I. Sanz)
2012:	Chair of Thesis Committee: Punsiri Colonne (Pathology; Mentor: S. Sahni)
2009-2012:	Sarah (Allen) McConnell, Dept. of Neurobiology & Anatomy (Mentor: M.K. O'Banion)
2009-2013:	Emilio Ortiz-Riaño#, Dept. of Microbiol and Immunol (Mentor: L. Martínez-Sobrido)
2009-2013:	Sarah VanCor-Hosmer, Dept. of Microbiol and Immunol (Mentor: B. Kim)
2010-2013:	Dan Marker, Dept. of Microbiol and Immunol (Mentor: H. Gelbard)
2012-2013:	*Michele Daly, Dept. of Microbiol and Immunol (Mentor: B. Kim). Michele transferred to Emory University to complete her Ph.D. in 2013*
2010-2013:	Amita Vaidya, Dept. of Biology (Mentor: V. Gorbunova)
2010-2013:	John Muchiri#, Dept. of Biochemistry and Biophysics (Mentor: R. A. Bambara)
2011-2013:	Sarah Amie, Dept. of Biochemistry and Biophysics (Mentors: R. A. Bambara and B. Kim)
2010-2013:	Waaqo Daddacha, Dept. of Microbiol and Immunol (Mentor: B. Kim)
2009-2014:	Will McDougall, Dept. of Biochemistry and Biophysics (Mentor: H. Smith)
2011-2014:	Cindi Lewis#, Translational Biosciences Ph.D. program (Mentor: A. Alio)
2010-2015:	Steve Baker, Dept. of Microbiol and Immunol (Mentor: L. Martínez-Sobrido)
2011-2015:	Benson Cheng, Dept. of Microbiol and Immunol (Mentor: L. Martínez-Sobrido)
2016:	Chair of Thesis Committee: Heather Elder, Epidemiology Program
2012-2017:	Ryan Connor, Dept. of Microbiol and Immunol (Mentor: S. Maggirwar)
2012-2017:	Anthony DiPiazza, Dept. of Microbiol and Immunol (Mentor: A. Sant)
2015-2018:	Maxime Jean# (MD/PhD), Dept. of Microbiol and Immunol (Mentor: J. Zhu)
2014-2019:	Irene Rodríguez-Sánchez, Dept. of Microbiol and Immunol (Mentor: J. Munger)
2017-2019:	Rohith Palli (MD/PhD), Dept. of Biochemistry and Biophysics (Mentor: J. Thakar)
2017-2021:	Kilean Lucas, Dept. of Biomedical Engineering (Mentor: J. McGrath)
2019-2023:	Jeff Beard, Dept. of Biomedical Engineering (Mentor: J. McGrath)
2020-2024:	Zhihui Zhang, Dept. of Biology (Mentors: V. Gorbunova, A. Seluanov)

<u>M.S. Thesis Committees (past)</u>

2016-2017:	Liz Albertorio-Saez, Dept. of Microbiol and Immunol (Mentor: C. Morrell)

<u>Ph.D. Thesis Committees (current and continuing)</u>

2020-pres.:	Lisette Alcantara#, Translational Biomedical Sciences (Mentor: K. Fiscella)

3. Postdoctoral Fellows, Research Assistant Professors & Others

Postdoctoral Trainees (Complete List)

#: member of under-represented racial/ethnic minority group (BIPOC)

1992-1995: Sheila C. Dollard, Ph.D. *Current Position: Lab Director (Faculty Equivalent), Herpesvirus Section, Centers for Disease Control and Prevention, Atlanta, GA.*

1994-1997: Nanette M. van Loon, Ph.D. *Current Position: Associate Professor of Genetics, City University of New York, Manhattan Borough Community College, New York, NY.*

1996-1998: Dina Markowitz, Ph.D. *Dr. Markowitz was a non-research postdoctoral fellow whom I supervised when she first started at UR. Current Position: Professor, Dept. of Environmental Medicine, URMC; Director, Life Sciences Learning Center (LSLC), URMC*

1997-1998: Linda Whetter-Stefanski, D.V.M., Ph.D. *Current Position: See below*

1997-2000: Harshawardhan Bal, Ph.D. *Current Position: President, Shilpa Pharma Inc., PA*

1997-2000: David Skrincosky, Ph.D. *Current Position: Technical Director, Worthington Biochemicals, Freehold, NJ.*

1998-1999: Jay McLaughlin, Ph.D. (joint supervisor with J. Bidlack). *Current Position: Professor, University of Florida, Gainesville, FL*

2000-2002: Xiuqing Wang, D.V.M., Ph.D. *Current Position: Professor, Dept. of Biology and Microbiology, South Dakota State University, Brookings, SD.*

2001-2003: Shongshan (Sam) Fan, Ph.D. Appointed as *Research Assistant Professor, URMC from 2003-2006. Current Position: See below*

2001-2005: Birgit Bradel-Tretheway, Ph.D. *Current Position: See below*

2004-2005: Servio Ramirez#, Ph.D. *Current Position: See under Ph.D. students.*

2004-2008: Christine Sanfilippo, Ph.D. *Current Position: Senior Manager, Pharmaceutical Medical Affairs, Bausch + Lomb, Rochester, NY*

2006-2010: Oksana Polesskaya, Ph.D. *Current Position: See below*

2007-2008: Ramil Sapinoro#, Ph.D. *Current Position: see under Ph.D. students*

2008-2011: Jonelle Mattiacio, Ph.D. *Current Position: See below*

2010-2012: Fernando Ontiveros#, Ph.D. *Current Position: Associate Professor, Biology, St. John Fisher College, Rochester, NY; Founder, PETL Fluidics*

2023-2024: Raven Osborn#. Co-mentor with Juilee Thakar. *Current position: See under Ph.D. students.*

Research Assistant Professors or Instructors

1997-2001: Sanjay Maggirwar, Ph.D. *Current Position: Chair, Microbiology and Immunology, George Washington University, Washington, DC*

1999-2001: Linda Whetter-Stefanski, D.V.M., Ph.D. *Current Position: Retired*

2003-2006: Shongshan Fan, Ph.D. *Current Position: Associate Team Lead, QPS Holdings LLC, Newark, DE*

2005-2009: Birgit Bradel-Tretheway, Ph.D. *Current Position: Adjunct Instructor, Lewis-Clark State College, Spokane, WA*

2009-2010: Qingfu Xu, Ph.D. (Instructor). *Current Position: Research Scientist II, Rochester General Hospital Research Institute*

2011-2014: Jonelle Mattiacio, Ph.D. *Current Position: Associate Professor, Biology, St. John Fisher College, Rochester, NY*

2010-2014: Oksana Polesskaya, Ph.D. *Current Position: Scientific Coordinator, University of California, San Diego*

Others

2007-2010: Marlene Boutet, MS, MBA. Administrator, UR Developmental Center for AIDS Research. *Current Position: Director, Office of Research, The Jackson Laboratory, Bar Harbor, ME*

2010-2014: Jennifer Lynch, MS, MBA. Administrator, UR Center for AIDS Research (previously a Developmental Center for AIDS Research). *Current Position: Director of Clinical Operations, STAAR Surgical*

2012-2017: Michael J. Fiske, MS. Executive Director and Manager, Upstate Stem Cell cGMP Facility at the University of Rochester. *Current Position: Vice President, Manufacturing Science & Technology, Regenerative Science, Inc., Manhattan Beach, CA*

2015-2019: Laura Enders, BAAS, BSN, RN, MBA. Administrator, UR Center for AIDS Research. *Current Position: Director of Finance and Administration, Dept. of Social Medicine, School of Medicine, University of North Carolina at Chapel Hill*

2017-2020: Luísa Caetano-Davies, PhD. Facility Manager (2017-2018) and Executive Director (2019-pres.), Upstate Stem Cell cGMP Facility at the University of Rochester. *Current Position: Associate Director, Manufacturing Technologies, Cell Therapies (Development and Automation), Takeda, Boston, MA*

2017-2021: Charmaine Wheatley, BFA. URMC Artist-in-Residence. *Current Position: Artist-in-Residence, Del Monte Institute for Neuroscience, University of Rochester*

2020-2021: Brianna (Shares) Kalicharan, PhD. Interim Director and later Director University of Rochester Cell Therapy Manufacturing Facility (CTMF)*,**. **: This is re-branding of the Upstate Stem Cell cGMP Facility; **: The CTMF closed in early 2021. Current Position: Director of Manufacturing, Vita Therapeutics, Baltimore, MD*

4. Undergraduate Students

Research Trainees – Complete List

#: member of under-represented racial/ethnic minority group (Black or Latinx)

1991-1992: Hyun S. Song, Kyrie Altmann (MBI 395)

1992-1994: Solam Tsang (HHMI summer scholar)

1993-1994: Daniel Sherwood (MBI 395, summer, Honors Thesis)

1994:	Ruby Marentes[#] (McNair summer scholar)
1994-1995:	Helen Chan (MBI 395, HHMI summer scholar, Honors Thesis)
1995:	Seth Nosel (MBI 395), Shabnam Bakshi (MBI 395)
	Julia Simmons[#] (SURF summer scholar)
1996:	Jeffrey Livingston-Carr (MBI 395), Joy Conte (MBI 395)
	Sampada Deshpande (MBI 395)
	Jodie Dionne (HHMI summer scholar)
	Victoria Croog (SCRC summer scholar)
1997:	Caryn Picarillo (MBI 395), Anh Tieu (MBI 395)
	Jennifer Blender (summer scholar)
	Mary Fudge (MBI 395, HHMI summer scholar)
	Jodie Dionne (MBI 395, De Kiewiet summer scholar)
1998:	Christy Cianfrini (MBI 395), Jennifer Blender (MBI 395), Johnathan Eng (MBI 395)
	Eva Bender (SCRC summer scholar, MBI395), Wendy Goodman (SCRC summer scholar), Michael Sung (SCRC summer scholar, MBI 395)
1999:	Eva Bender (MBI 395), Johnathan Eng (MBI 395), Greg Gregory (MBI 395)
	Melody Walsh (MBI 395, GEBS summer scholar), Sarah Henninger (DeKiewiet summer scholar), Jamal Mitchell[#] (McNair summer scholar, MBI 395)
2000:	Greg Gregory (MBI 395, Honors Thesis), Sarah Henninger (MBI 395, DeKiewiet summer scholar); Trisha Kline (GEBS summer scholar, MBI 395); David Stubbs[#] (SURF summer scholar) Anthony Fama (MBI 395), Navneet Virk (MBI 395)
2001:	Trisha Kline (MBI 395); Michael Freeman (GEBS summer scholar); Johanna Abend (GEBS summer scholar; MBI395); James Bradley[#] (SURF summer scholar; MBI 395)
2002:	Johanna Abend (MBI 395; GEBS summer scholar, with Julie Richards); James Bradley[#] (MBI 395; comentored with S. Maggirwar); Amanda Genaux (GEBS summer scholar, with Birgit Bradel-Tretheway); Mark Skasko (GEBS summer scholar, with Ramil Sapinoro); Tatiana Garcia[#] (GEBS summer scholar, with Servio Ramirez)
2003:	Johanna Abend (MBI 395, with Julie Richards); Angela Burgess[#] (GEBS summer scholar, with Ramil Sapinoro); Cristina Capella-Gonzalez[#] (GEBS summer scholar, with Ramil Sapinoro); Jenny Shen (GEBS summer scholar, with Shongshan Fan); Natasha Girgis (MBI 395; GEBS summer scholar, with Casey Maguire)
2004:	Jan Wong (MBI 395, with Christine Zanghi); Pat Hanley (spring intern, summer trainee, with Cindy Duke); Timaris Demott[#] (GEBS summer scholar, with Servio Ramirez); Erin Conway (GEBS summer scholar, with Kathy Santos)

2005:	Erin Conway (MBI 395, with Kathy Santos); Peter Mukwevho (GEBS summer scholar, with Crisy Sanfilippo); Anthony Dakwar (GEBS summer scholar, with Cindy Duke); Tony Broyld# (informal independent research)
2006:	Robert Chow (MBI 395, with Ketna Volcy); Tony Broyld# (informal independent research, with Crisy Sanfilippo); Anthony Dakwar (GEBS summer scholar, with Cindy Duke); Talin Robinson# (GEBS summer scholar with Cristina Capella)
2007:	Adam Bailey (GEBS summer scholar), Rumbidzayi Nzara (GEBS summer scholar), Stefanie Trop (UR summer student), Daniel Berman (GEBS summer scholar), Stefanie Trop (MBI 395, Fall), Benjamin Misemer (MBI 395, Fall), Chelsea McGuire (work/study, Fall), Aaron McUmber (MBI 395, Fall)
2008:	Stefanie Trop (MBI 395, Spring; MBI 395 Fall), Benjamin Misemer (MBI 395, Spring), Chelsea McGuire (MBI 395, Spring; De Kiewiet summer fellowship; MBI 395 Fall), Aaron McUmber (MBI 395, Spring); David Collins (Summer); Quiana Reed# (Summer TPOID trainee); Egberanmwen (Egbe) Ode# (Summer SURF trainee); Joanna Attardo (summer volunteer); Michael-John Beltejar (SUNY Brockport, volunteer, fall)
2009:	Michael-John Beltejar (SUNY Brockport, Senior Honors Thesis; Spring, Summer). David Collins (MBI 395, Spring). Stefanie Trop (MBI 395, Spring). Taylor Desrosiers (summer, with Oksana Polesskaya); Cristina Ortiz-Diaz# (GEBS summer scholar); Kelsey Thomas (GEBS summer scholar with Jonelle Mattiacio); Catherine Stevenson (MBI 395, Fall with Jonelle Mattiacio); Marika Osterbur (MBI 395, Fall, with Vincent Fong); Johnny Ting Zheng (volunteer, with Oksana Polesskaya)
2010:	Catherine Stevenson (MBI 395, Spring & Summer, with Jonelle Mattiacio); Marika Osterbur (MBI 395, Spring, with Vincent Fong); Paul Blackcloud (Post-bacc. Trainee, medical school entry program; Spring); Johnny Ting Zheng (MBI 395, Spring & Summer, with Oksana Polesskaya); Michael-John Beltejar (SUNY Brockport, Senior Honors Thesis; GEBS summer research with Cristina Capella); Kelsey Thomas (GEBS summer scholar; with Jonelle Mattiacio); Jo-El (Joel) Kim (GEBS summer research with Vincent Fong); Gabriela Palacio# (SURF program; with Will Domm); Alex Vostal (volunteer)
2011:	SPRING: Stephanie Kwakye# (MBI 395, Spring, with Oksana Polesskaya); Alex Vostal (MBI 395, Spring); Enoch Chan (MBI 395, Spring, with Jonelle Mattiacio); Catherine Stevenson (MBI 395, Spring, with Jonelle Mattiacio)
	SUMMER: Catherine Stevenson (awarded a DeKiewiet Fellowship, with Jonelle Mattiacio); Johnny Ting Zheng (with Oksana Polesskaya); Felix Ramos# (GEBS Summer Scholar – U. PR, Rio Piedras; with Oksana Polesskaya); Tenee Lopez# (NIDA sponsored summer student on an individual NIH minority summer supplement; U. Texas, Brownsville; with Jharon Silva); Brittany Ross (with David Easterhoff); Brandon McDonald# (with Jonelle Mattiacio)

	FALL: Stephanie Kwakye# (MBI 395, Fall, with Oksana Polesskaya); Johnny Ting Zheng (volunteer; with Oksana Polesskaya); Jason Audlin (MBI 395, Fall, with Will Domm)
2012:	SPRING: Brandon McDonald# (MBI 395, with Jonelle Mattiacio); Yoel Kim (MBI 395, with David Easterhoff); Johnny Ting Zheng (volunteer; with Oksana Polesskaya); Jason Audlin (volunteer; with Will Domm); Joynita Sur (temporary volunteer; with Oksana Polesskaya)
	SUMMER: Janelle Veazey (GEBS Summer Scholar - Messiah College; influenza); Kaitlyn Jefferson# (GEBS Summer Scholar - U South Dakota; HIV transmission/SEVI); Phillip Cohen (GEBS Summer Scholar – UR; with Oksana Polesskaya); Iris Zhang (volunteer – Union College; with Oksana Polesskaya)
	FALL: Woori Bae (MBI 395W, with David Easterhoff). Jason Audlin (MBI 395, with Will Domm); Chris Nishimura (IND 395, with Oksana Polesskaya); Phillip Cohen (work/study; with Matt Brewer); Yoel Kim (MBI 395; with David Easterhoff); Audra Gold (volunteer; with Oksana Polesskaya)
2013:	SPRING: James Wu (MBI 395; with Colleen O'Dell); Audra Gold (MBI 395; with Oksana Polesskaya); Chris Nishimura (MBI 395; with Oksana Polesskaya); Phillip Cohen (work/study; with Matt Brewer); Divya Kumar (short-term volunteer; with Jeff Chamberlain and Jharon Silva)
	SUMMER: Phillip Cohen (DeKiewiet Fellow; w. Matt Brewer); Chris Wong (Early Acceptance Program, UR Medical School class; with Oksana Polesskaya); Laura Keenahan (GEBS Summer Scholar; with Lauren Brooks); Kaleb Roush (GEBS Summer Scholar; w. Matt Brewer); Audra Gold (GEBS Summer Scholar; w. Oksana Polesskaya); Wenying (Cherry) Guo (Zhejiang University Summer Scholar; w. Jonelle Mattiacio)
	FALL: Chris Nishimura (MBI 395, w Oksana Polesskaya); Eun Hee (Hannah) Lee (MBI395W, w. Jonelle Mattiacio)
2014:	SPRING: Laura Keenahan (MBI 395W; w. Lauren Fischer); Philip Cohen (MBI 395 and Honors Thesis; w. Matt Brewer); Jamie Strampe (MBI395; w. Matt Brewer); Shiv Patel (w. Jonelle Mattiacio); Chris Nishimura (w Oksana Polesskaya); Steven Maisto (St. John Fisher College, w. Jeff Chamberlain); Daniel Van Twist (general lab assistant w. Jeff Chamberlain)
	SUMMER: Jamie Strampe (deKiewiet Summer Fellowship; w. Matt Brewer); Rachel Siliciano (GEBS summer scholar, from Colgate University; w. Oksana Polesskaya); Jordana Schmierer (GEBS summer scholar, from UR; w. Andy Cox); Phil Cohen (4 week summer research; w. Matt Brewer); Chris Nishimura (w. Oksana Polesskaya); Lili Yu (Zhejiang University Summer Scholar; w. Dorota Piekna)
	FALL: Jamie Strampe (MBI395; w. Matt Brewer); Jordana Schmierer (MBI395; w. Andy Cox); Chris Nishimura (MBI395, w. Oksana Polesskaya); Laura Keenahan (MBI 395; SEVI w. Lauren Brooks)
2015:	SPRING: Jamie Strampe (MBI395 and Honors Thesis; w. Matt Brewer); Jordana Schmierer (MBI395 and Honors Thesis; w. Andy Cox); Chris Nishimura (Honors Thesis)

	SUMMER: Jordana Schmierer (w. Andy Cox); Lemlem Baraki (volunteer, w. Matt Brewer)
	FALL: None
2016:	SPRING: Jordana Schmierer (w. Andy Cox); Josh Acklin (w. Matt Brewer)
	SUMMER: Maya El Ghouayel (MS1, w. Andrew Smith); Josh Acklin (awarded a DeKiewiet Summer Fellowship; w. Matt Brewer); Dustyn Levenson (awarded an independent UR Summer REACH fellowship; w. Matt Brewer)
	FALL: Emily Ivey (w. Matt Brewer)
2017:	SPRING: Emily Ivey (w. Matt Brewer)
	SUMMER: Emily Ivey (awarded an independent UR Discover grant; w. Matt Brewer)
	FALL: Maya El Ghouayel (MS2, w. Andrew Smith)
2018:	None
2019:	SPRING: Sarah Belanger (w. Jeff Chamberlain)
	SUMMER: Sarah Belanger, Kara Farquharson# (BRIDGES Scholar; Deaf)
	FALL: Sarah Belanger, Kara Farquharson# (BRIDGES Scholar; Deaf)
2020:	SPRING: Sarah Belanger
	SUMMER: Bryan Zuniga# (McNair Program)
	FALL: Bryan Zuniga# (McNair Program), Julia Tang (w. Justin Leach)
2021:	SPRING: Lydia Levesque (w Raven Osborn), Bryan Zuniga# (McNair Program), Julia Tang (w. Justin Leach)
	SUMMER: Jael Ernest Fleurant# (w Raven Osborn)
	FALL: Bryan Zuniga# (McNair Program), Julia Tang (w. Justin Leach), Jael Ernest Fleurant# (w Raven Osborn)
2022:	SPRING: Bryan Zuniga# (McNair Program), Jael Ernest Fleurant# (w Raven Osborn)
	SUMMER: Jael Ernest Fleurant# (w Raven Osborn), LouLou Martell deVallance (NSF REU w Sebastian Bosch)
	FALL: Jael Ernest Fleurant# (w Sebastian Bosch)
2023:	SPRING: Julia Tang (w. Justin Leach)
	SUMMER: Trinity King# (w Sebastian Bosch), Lexus Fuller# (w Justin Leach)
	FALL: Lexus Fuller# (w Justin Leach)

5. K-12 Students

High School Students (Research Experiences - Previous)

2012:	Aaron Appelle (summer HS student, Brighton High School; w L. Brooks)
2013:	Alex Karam (summer HS student, Brighton High School; w L. Brooks)

High School Students (Shadowing Experiences – Previous)

High-school students unless otherwise indicated

2014: Erin Kesel (Canandaigua Academy; with Oksana Polesskaya)

2014: Nick Lahue (Penfield HS; with Oksana Polesskaya)

6. Continuing Medical Education

2012: Keynote Speaker on "Eradication of HIV Infection", annual HIV Clinical Conference, UR (May 2012). *The conference is supported in part by the Clinical Education Initiative (CEI) from the NYS DOH AIDS Institute and attracts about 250-300 clinicians from a 10 county area.*

B. Professional Service

Past 10 years and selected prior

B1: Institutional Service Activities

B1(A): Department of Microbiology & Immunology

2011: **Chair**, Bacteriology Search Committee, Dept. of Microbiology and Immunology. *Hired Steve Gill and Paul Dunman.*

2012: Member, Bioinformatics Search Committee, in conjunction with the Center for Integrative Bioinformatics and Experimental Mathematics (CIBEM) in the Department of Biostatistics and Computational Biology (Hulin Wu, chair). *Hired Juilee Thakar.*

2012-13: **Chair**, Virology Search Committee, Virology Faculty member, Dept of Microbiology and Immunology, URSMD. *Hired Jian Zhu.*

2012-14: Member, Search Committee, Immunology Faculty member, Immunology & Infectious Diseases program; URSMD. *Hired Felix Yarovinsky.*

2012-2013: Coordinated successful effort to establish a new biopharma internship program in the Department of Microbiology & Immunology (director: Paul Dunman).

2012-2015: Coordinated successful effort to establish a new Master of Science in Technical Entrepreneurship and Management in Biomanufacturing and Therapeutic Development (TEAM-BMTD) program. This new TEAM MS degree program was approved by New York State in May, 2015; and the program was launched in fall 2016 with an initial class of 6 domestic students

2014-2015: Coordinated effort to update and streamline the Ph.D. curriculum in Microbiology and Immunology, with the goal of creating a one-year didactic curriculum. This involved reorganization and/or consolidation of

multiple courses, as well as making several courses available annually (rather than semi-annually).

2018-2019: Member, Virology Search Committee (Chair = Brian Ward), Virology Faculty member, Dept of Microbiology and Immunology, URSMD. *Hired Yiping Zhu (Assistant Prof)*

2019-2020: Member, Virology Search Committee (Chair = Brian Ward), Virology Faculty member, Dept of Microbiology and Immunology, URSMD. *Hired Ruth Serra-Moreno (Associate Prof) and Yan Sun (Assistant Prof)*

B1(B): School or Institution-Wide Activities

1991-present: Interviewer for applicants to various URMC programs, including:

- Ph.D. programs in Immunology, Microbiology & Virology; Neuroscience; Translational Biomedical Sciences
- M.D./Ph.D. program

1992-2007: University of Rochester Institutional BioSafety Committee

- **Chair**, 1996-2007

1994-pres.: Reviewer, UR intramural pilot research grant award programs and related activities – including CFAR pilot awards; CTSI pilot awards; Drug Discovery program awards; Goergen Institute for Data Science (GIDS) pilot awards; Greater Rochester Health Foundation; HSCCI pilot awards; University Research Awards; Wilmot Cancer Institute pilot awards

1994-pres.: Reviewer, UR intramural training grant appointments and related activities – including CTSI KL2 awards; HIV/AIDS predoctoral training grant; PREP training program; NYS stem cell training program

2000-pres.: Member, institutional search committees for various faculty and leadership positions – including positions in academic departments and administrative units.

<u>Recent academic department searches</u> have included:

- *Chief, Allergy, Immunology and Rheumatology Division [2011; hired Chris Ritchlin];*
- *Director, URSMD Research Core Facilities [2012; hired Tim Bushnell];*
- *Director, Del Monte Neuromedicine Institute [2013-2015; hired John Foxe];*
- *Director, Center for Biomedical Informatics [2014-2016; ultimately appointed Dirk Bohmann]*
- *Chief, Infectious Diseases Division [2017-19]; placed on hold, in order to recruit a new chair of Medicine*
- ***Search Chair:** Vice Chair for Research, Dept. of Pathology and Laboratory Medicine [2019-2020]; placed on hold due to COVID-19 and its related financial impact*

<u>Recent administrative unit searches</u> have included:

- *Associate Vice President for Innovation and Technology Commercialization, UR [2012; hired Scott Catlin];*
- *Director, Eastman Institute of Oral Health [2012-2013; hired Eli Eliav],*

- ***Search Chair:*** *Sr. Associate Dean for Basic Science [2014; appointed Dirk Bohmann];*
- *Chief Financial Officer, URMC [2014; hired David Kirshner];*
- *Vice Dean for Research, School of Nursing [2014-2015; hired Kim Arcoleo];*
- *Vice President for Communications, UR [2014-2015; hired Elizabeth Stauderman];*
- ***Search Chair:*** *Director, Research IT, SMD [2015; hired Steven Wormsley];*
- ***Search Chair:*** *Sr. Associate Dean for Clinical Reseach [2016; appointed Jill Halterman];*
- *Dean of the Faculty (River Campus) [2016-2018; hired Donald Hall];*
- ***Search Chair:*** *Director, Office of Clinical Research [2017-2018; hired Pat Ames]*
- *Director, Goergen Institute for Data Science (GIDS) [2018-2020; appointed Mujdat Cetin]*
- *Sr. Associate Dean for Clinical Research [2018; appointed Martin Zand]*
- *Sr. Associate Dean for Graduate Education [2018; appointed Rick Libby]*
- ***Search committee member for new UR President****, [2018-2019] (member of faculty advisory committee; hired Sarah Mangelsdorf, former Provost at U-Wisconsin)*
- *Sr. Associate Dean for Finance and Education [2019; hired Gerard Mikols]*
- ***Oversaw recruitment of new Associate Vice President and Director of UR Ventures*** *[2021; hired Harl Tolbert, the first African-American/Black individual to serve in this role at the University]*
- ***Oversaw recruitment of new Deputy Director of the Laboratory for Laser Energetics (LLE)*** *[2021; hired Chris Deeney]*
- ***Oversaw recruitment of the new full Director of the LLE*** *[2022; hired Chris Deeney; engaged Opus Partners to facilitate this search]*
- *Search committee member, Vice President for Marketing and Communications [2023; recruited Page Hetzel]*
- ***Overseeing recruitment of the new Associate Vice President for Human Subjects Protection*** *[2023; recruited Elizabeth Campbell; engaged Opus Partners to facilitate this search]*
- *Search committee member, CEO of the University Rochester Medical Center, Dean of the School of Medicine and Dentistry and Senior Vice President for Health Sciences at the University of Rochester [2023; recruited David Linehan]*
- *Search committee member, architectural consultant presentations for Institutional Facilities Master Plan [2023]*
- ***Overseeing recruitment of a new full-time Research Integrity Officer*** *[2024; in progress; engaged Opus Partners to facilitate this search]*
- *Interviewer, candidates for Associate Vice President of Public Safety and Chief Public Safety Officer [2024; ongoing]*

1998-2005:	**Director**, GEBS Summer Scholars Program (Undergraduate Summer Research Program at UR)
2000-2005:	**Director**, NSF REU Site in Cellular and Molecular Biology at Rochester (Undergraduate Summer Research Program at UR, funded by NSF)
2000-2002:	**Director**, UCIS Cluster in "Molecular discovery and directed evolution"
2001-2004:	**Senate Member**, University of Rochester Faculty Senate
2005-07:	**Chair**, Scientific Publishing Committee, URMC
2005-09:	Member and **Chair** (2007-2009), Intellectual Property Advisory Committee (IPAC), URMC
2007-2012:	Member, UR Technology Transfer Policy Committee. *This small committee oversaw technology transfer activities at UR, and was led by Provost Kuncl.*
2007-2015:	Member, Scientific Advisory Board, Center for Biophysical Assessment and Risk Management Following Irradiation (aka CMCR; Paul Okunieff, PI from 2007-2009; Jackie Williams, PI from 2010-2015). This award ended in 2015.
2007-pres.	Member, Medical School Advisory Committee (MEDSAC), URSMD.
2007-pres.:	Member, Executive Committee, Ph.D. Program in Translational Biomedical Sciences (TBS).
2007-2013:	Member, Conflict of Interest Committee, UR
2007-2009:	**Director,** URSMD Interim Funding Program
2007-2009:	**Director,** Dean's Research Advisory Committee (DRAC)
2007-2009:	**Director,** URSMD Faculty Research Incentive Programs
2008-2009:	**Chair,** cGMP Facility Committee Planning Group. *This effort concluded with the design, construction and launch of a stem cell cGMP facility on the URMC campus, funded by New York State. The facility opened in 2011.*
2008-2009:	**Co-Lead,** Teacher-Institutional-Scholar option for faculty promotion. *This new faculty option at the URSMD recognized faculty with major institutional roles/responsibilities that cross multiple departments - such as directors of URSMD Core Facilities and others. It was introduced as an amendment to the URSMD Regulations of the Faculty, and was developed in consultation with Dean Richard Burton, Andrea Sant and others.*
2009-2015:	Member, Executive Governing Board, Health Sciences Center for Computational Innovation (IBM High-Performance Computing Center)
2009-2014:	Member, MEDSAC Steering Committee. *This committee evaluates all faculty promotions at URSMD. Invited to serve 2 consecutive terms. I remain an ex officio member of this group.*
2009-2013:	Member, Conflict of Interest Committee (CIAG), URSMD
2009-2013:	Member, Mentor Development Core for the Research, Training and Career Development Key Function of the UR CTSI
2010:	Member, Review Panel for NIEHS Center and Toxicology Training Program, Dept. of Environmental Medicine (Tom Gasiewicz, Director)

2010:	Member, URSMD Working Group on Tenure.
2010-pres:	Participant, UR Year One Symposia for new faculty (discussant on panels on grant funding, academic careers)
2010:	Member, Steering Committee, URSMD High-Throughput Screening Core. *Also developed new website for Virtual Drug Discovery Core.*
2010-2013:	Member, Animal Resource Advisory Committee (Jeff Wyatt, Chair)
2010-2015:	Member, SURG (Sponsored University Research Group) Committee (University-wide)
2010-2011:	**Chair**, URSMD Working Group on Productivity Based Compensation for Research/Teaching.
2011:	**Co-Founder** (w. Paul Dunman) of the UR-Moulder Center Partnership for drug discovery and development
2011-2021:	Member, Steering Committee, Immunology and Infectious Diseases Research Program of Excellence, URMC (other members: Tim Mosmann, John Treanor [since retired], Dave Topham, Ann Falsey)
2012-2016:	Contributor/blogger, Rochester Democrat and Chronicle blog on Rochester's Innovation Economy (coverage on entrepreneurship and innovation). Contributed approximately one post/week. *http://blogs.democratandchronicle.com/rocnext/author/sdewhurst/*
2013:	Member, Working Group on Tenure and Promotion (chair: Jeff Lyness)
2013:	Participant, Cardiovascular Research Institute (CVRI) strategic planning retreat
2013-pres:	Member, URSMD Space Committee
2013-pres:	Member, Associate Deans Executive Planning Team (ADEPT), URSMD
2013-pres:	**Senior Advisor**, Junior Biomedical Research Faculty Association (JBRFA) – a peer mentoring group for junior faculty at URSMD
2013-2016:	**Chair (2013-2015) or Co-Chair (2015-2016),** SMD Scientific Advisory Council (SAC). Faculty group charged with oversight of the UR SMD research strategic plan.
2013-2015:	**Chair**, Academic IT Faculty Group (URMC). Group charged with improvement and oversight of research and education IT at the URMC.
2013-pres:	**Coordinate and develop** research partnering initiatives with potential private sector partners, or other partners - including Indivumed, Geisinger Health System, IBM, MC10, OmniSEQ, Regeneron, Xerox
2014-pres.:	**Review Coordinator**, University Research Award program (intended to support innovative multidisciplinary research across UR)
2014:	Participant, Middle States Accreditation review
2014-2021:	**Co-Director**, HIV/AIDS Research Program of Excellence, URSMD (with Mike Keefer, Jim McMahon)
2014-2019:	**Co-Leader** (w. Jeff Lyness, Dick Burton (since retired), Lissa McAnarney), Leadership Seminar for Chairs and Center Directors
2014	Member, UR SMD Liaison Committee on Medical Education (LCME) standards taskforces for (1) Standard 1: Mission, Planning, Organization, and Integrity; Standard 2: Leadership and Administration; Standard 4:

	Faculty Preparation, Productivity, Participation, and Policies and (2) Standard 3: Academic and Learning Environments. *Self-study process in preparation for LCME survey team visit in October 2015.*
2015-pres.:	Member, President's Cabinet, UR. *This committee is advisory to the UR President.*
2015-2019:	Annual Member, Faculty Jury, UR Falling Walls Lab. *Young researchers, PhDs, MA students and postdocs presented their innovative ideas, business models or research projects in a 3-minute talk to an interdisciplinary audience. The winner was selected to represent UR at the global Falling Walls lab/conference in Berlin. in 2018, the UR nominee (Ahmed Ghazi) won this global competition.*
2014-2015:	**URMC Lead Contact**, partnership with Indivumed – led to creation of the Rochester Cancer Library (a new genome-quality cancer tissue bank; see below) and to a subsequent research partnership, including sequencing of 1,000 cancer genomes (with matched normal tissue) and development of an informatics portal (lead: Hucky Land)
2016-2018:	Executive Committee Member, Rochester Cancer Library (URMC-Indivumed partnership). 3 year, $2M cancer biobank agreement (lead: David Linehan)
2016-2017:	Faculty Jury, UR 3 Minute Thesis Competition. *Graduate students presented their thesis projects in a 3-minute talk format.*
2016:	Co-Organizer, Health Data Retreat, URMC and UR Goergen Institute for Data Science (lead: Martin Zand)
2016-2021:	Member, URMC Executive Committee on Diversity and Inclusion (chair: Adrienne Morgan [formerly, Linda Chaudron])
2016-2018:	Member, Search Committee, Dean of the Faculty (UR)
2017:	Member and **Alternate Chair**, University of Rochester Research Strategic Planning Committee (lead: David Williams). *This committee was put on hold with the resignation of President Seligman in early 2018.*
2017:	Judge, Scientific Poster Session, UR Postdoctoral Appreciation Day
2017:	**Chair**, The Del Monte Neuroscience Institute Science Advisory Board. *Chaired the proposal review committee, which selected 4 programs to function as the core components of DMNI's Research Strategic Plan.*
2018-pres:	Member, Internal Advisory Board, UR NIH P50 CORT (Center for Orthopaedic Research & Translation) on Osteoimmunology of Bone Infection
2018-pres:	Member, Internal Advisory Board, UR NIH MSTP (Medical Scientist Training Program)
2018-2019:	Member, cGMP Facility Committee Planning Group. *Developed and implemented plans to add additional production rooms to the facility. This expansion was not pursued due to funding constraints.*
2019-pres.:	Member, Art on Campus committee
2019-2022:	Member, Internal Advisory Board, UR Wilmot Cancer Institute (WCI)

2019-2020:	Member, 2020 Collaborative committee (chair: Adrienne Morgan); *this committee was charged with recognizing the 100th Anniversary of the 19th Amendment and the 200th Anniversary of Susan B. Anthony's birth.*
2019-2022:	*Member,* AIDS Posters Project Advisory Board; *this committee helped to develop a traveling exhibition of the UR's unique Atwater AIDS Posters collection (with an initial installation at the UR's Memorial Art Gallery in 2022 under the title "Up Against the Wall")*
2021-pres.:	**Chair,** Research Executive Committee; *this committee coordinates and oversees research activities across the UR campus.*
2021-pres.:	**Co-Chair**, Committee on Science and Security; *this committee assesses and implements practices to protect the University's research enterprise from unauthorized foreign access or influence.*
2021:	Member, planning group, Build Back Better Regional Challenge (BBBRSC) proposal to the U.S. Economic Development Agency (EDA). PI of the submitted Phase I proposal in 09/2021.
2021-pres.:	Member, Operational Excellence Committee; *this committee oversees and advises on University operations*
2021-pres.:	**Faculty Lead**, UR Board of Trustees Research & Innovation Committee
2021-2022:	Member, Coronavirus University Restart Team (CURT 2.0).
2021-pres.:	Member, University Data Governance Council
2021-pres.:	Member, Technology Commercialization Advisory Committee (TCAC)
2021-pres.:	Member, Senior Leadership Group; *this committee comprises the direct reports to UR President Sarah Mangelsdorf*
2021-pres.:	**Co-Chair,** Research Data Ownership Policy Committee; *this committee drafts policy on the ownership of research data*
2021-2022:	Member of University Leadership Team, overseeing a review of UR graduate programs by the Council for Graduate (Chair: Melissa Sturge-Apple)
2021-2022:	Member, Sustainability Planning Advisory Board, GreenerU environmental sustainability initiative
2021-2022:	Member, Global Engagement Strategic Planning Committee (Chair: Jane Gatewood)
2021:	Reviewer and committee member, CTSI pilot grant review committee
2021-pres.:	Member, Endowed Professorship Reappointment Review Committee, URSMD
2021-pres.:	Member, Office of Equity and Inclusion (OEI) Advisory Committee, URSMD
2022-pres.:	*Ex officio* Member, Research Policy Committee
2022-2023:	Member, Liaison Committee on Medical Education (LCME) Self Study Task Force, UR SMD
2022-pres.:	Member, Wilmot Cancer Institute Executive Committee

2022-2023:	Member, Chartis Executive Committee *(consultant group providing advice on the administrative structure of the UR Med Center and UR Health System)*
2022-2023:	Member, Planning Committee, UR Board of Trustees Leadership Retreat (Washington DC, February 2023)
2023-pres.:	Member, Digital Transformation Executive Committee
2023-pres.:	University Master Plan Executive Steering Committee
2023-pres:	Member, Facilities Master Plan Executive Steering Committee
2023:	Member, UR SMD/SON Supreme Court of the US (SCOTUS) Race Based Admissions Committee
2024:	Consultant, UR RSRB review of proposed STUDY00008775, the HEROIC-PKP2 gene therapy study

B1(C): Faculty Mentoring

Past 10 years only – excludes grant consultations/reviews and informal career advice

2010-2014:	Mentor (or previously mentored) junior faculty in the UR CFAR, including David Adler (Emergency Medicine), Carrie Dykes (Infectious Diseases Division; now in the UR CSTI), Amy Jacobs (University of Buffalo), Ha Youn Lee (Biostatistics and Computational Biology; now at University of Southern California)
2010-pres.	Mentor (or previously mentored) junior faculty and new hires in the Department of Microbiology and Immunology, including Paul Dunman, Steve Gill, Luis Martínez-Sobrido (now at the Texas Biomedical Research Institute), Ruth Serra-Moreno, Yan Sun, Juilee Thakar, Brian Ward, Jian Zhu (now at Ohio State U), Yiping Zhu
2010-pres.	Mentor (or mentored) faculty at all career stages, including faculty on extramural grant awards: • Rusty Elliott (Center for Vaccine Biology; mentor on NIH CNIHR award, 2012-2014); • Brad Nilsson (Chemistry; mentor on NIH CNIHR award, 2010-2012); • Krupa Shah (Medicine/Geriatrics; mentor on NIH K23, 2013-2018, and mentor and CTSI KL2 award, 2012-2014). • Meera Singh (Neurology; co-mentor for transition from Res. Asst. Prof. of Micro to tenure-track Assistant Professor of Neurology); 2020-pres. • Margie Hodges Shaw (Health Humanities and Bioethics); 2020-present. *Nominated Dr. Shaw for the ELAM program (Executive Leadership in Academic Medicine)*
2020-pres.	Mentor/comentor (with Dr. Adrienne Morgan, the URSMD Sr. Associate Dean for Equity and Inclusion) non-tenure track URSMD faculty from groups historically excluded from biomedical research, including Black, Latinx(o/a) and Deaf individuals, with a view to enhancing their career progression. Recent successes include:

- Jermaine Jenkins. Promoted from non-tenure track Research Assistant Professor (RAP) to tenure-track Assistant Professor (Biochemistry and Biophysics), 2021.
- V. Kaye Thomas. Promoted from non-tenure track Research Assistant Professor (RAP) to tenure-track Assistant Professor (Pharmacology and Physiology), 2021.
- Francisco Cartujano Barrera. Promoted from non-tenure track Research Assistant Professor (RAP) to tenure-track Assistant Professor (Public Health Sciences), 2021.
- Calvin Cole. Promoted from non-tenure track Research Assistant Professor (RAP) to tenure-track Assistant Professor (Surgery), 2021.
- José Perez-Ramos. Promoted from non-tenure track Research Assistant Professor (RAP) to tenure-track Assistant Professor (Public Health Sciences), 2022.
- Wyatte Hall. Promoted from non-tenure track Research Assistant Professor (RAP) to tenure-track Assistant Professor (Public Health Sciences), 2022.
- Mechelle Sanders. Promoted from non-tenure track Research Assistant Professor (RAP) to tenure-track Assistant Professor (Family Medicine), 2022.

B2: Extramural Service Activities

B2(A): Editorial Assignments in Professional Journals

Journal Editing

2011-2014: Member, Editorial Board, Virology

2011-2013: Member, Editorial Board, Antiviral Therapy

2012-2014: Member, Editorial Board, Pathogens and Disease (formerly FEMS Immunology and Medical Microbiology)

Journal Reviewing

1991-present: *Ad hoc* reviewer for various journals, including Aging Cell, AIDS Research and Human Retroviruses, American Journal of Pathology, Annals of Neurology, Archives of Virology, Bioconjugate Chemistry, Biomaterials, Biotechniques, Biotechnology Progress, Blood, BMC Neuroscience, Brain Behaviour and Immunity, Clinical Infectious Diseases, Clinical Microbiology Reviews, Gene Therapy, Herpes, Journal of Biological Chemistry, Journal of Clinical Investigation, Journal of Clinical Microbiology, Journal of Clinical Virology, Journal of General Virology, Journal of Infectious Diseases, Journal of Medical Virology, Journal of Molecular Biology, Journal of Neurovirology, Journal of Virological Methods, Journal of Virology, Leukemia Research, Molecular Immunology, Molecular Medicine Today, Molecular Therapy, Mucosal Immunology, Nature Medicine, Nature Reviews Microbiology, Neurology, Neuroscience Letters, Neurotoxicology Reviews, Oncogene,

Pharmacological Research, PLoS ONE, PNAS, Science Translational Medicine

B2(B): Participation in Advisory and Research Review Committees

1999-2004: **Permanent Member and Chair** (2003-04), Acquired Immunodeficiency Syndrome Research Review committee (AIDSRRC), NIH (NIAID).

2002: **Chair,** NIAID Special Emphasis Panel for Review of Fogarty D43 Awards

2004-08: **Member**, NIH Recombinant DNA Advisory Committee (RAC).

2006-2015: Member, RAC Biosafety Working Group

2007-09: Member and **Co-Chair**, CTSA Public-Private Partnership (PPP) Steering Committee (with Bill Sandborn, Mayo Clinic)

2008-2014: **President** and Member, Board of Directors, Codevax Inc. (UR Vaccine Company; IRS EIN 26-2913996)

2008-2016: Member, Technical Advisory Board, Excell Partners (Rochester, NY)

2009: *Ad hoc* reviewer, NIH Review Panel "Immune Mechanisms of Virus Control" (IMVC); ZAI1-BDP-I-J3

2009: *Ad hoc* reviewer, NIH Special Emphasis Panel/Scientific Review Group 2009/10 ZRG1 AARR-D (02) [VACC, ADDT, ACE and AIP member conflicts]

2009: Reviewer, Homing Programme, International Programmes, Foundation for Polish Science, Warszawa, Poland. http://www.fnp.org.pl

2009: *Ad hoc* reviewer, NIH Scientific Review Group: ZDA1 SXC-E 5B 2, Biomarkers, Brain Development, Morphology, Genetics (ARRA GO)

2009-2010: Member, External Advisory Committee (EAC), Resource for Visualization of Biological Complexity, Wadsworth Center, Albany NY (NCRR-funded P41 biomedical technology center)

2009: *Ad hoc* Reviewer, NIH Review Panel for PAR-09-134, the "HIV Vaccine Research and Design (HIVRAD)" Program

2009: *Ad hoc* Reviewer, NIH T32 application on CNS HIV translational research

2010: Member, NIH Review Panel for Highly Innovative Tactics to Interrupt Transmission of HIV (HIT-IT) (R01) (RFA-AI-09-037); NIH 2010/05 ZAI1 BP-A (M2) 1

2010: Member and **Alternate Chair**, NIH Review Panel for "Basic HIV Vaccine Discovery Research (RFA-AI-09-024).

2010: *Ad hoc* Reviewer, NIH T32 application on CNS HIV translational research

2010: Member, NIH Review Panel for NIH/NIDA CEBRA Applications

2010: Member, NIH Review Panel for RFA-AI-09-022 "B cell Immunology Partnership Program for HIV-1 Vaccine Discovery (U19)"

2010: **Chair,** NIH Review Panel for RFA 10-014 entitled "Systems Biology, HIV/AIDS, and Substance Abuse"; NIH 2010/07 ZDA1 EXL-T 13

2010: Grant reviewer, Human Herpesvirus 6 (HHV6) Foundation

2010: Member, NIH Review Panel for HIVRAD RFA (HIV Vaccine Research and Design Program) (November, 2010)

2010*:*	Member, NIH Review Panel SEP/SRG ZRG1 AARR-J (02), for review of HIV/AIDS applications from members of the HIV Pathogenesis, Therapy and NeuroAIDS study section (Dec 2010)
2010:	Member, NIH Special Emphasis Panel for NIDA RFA DA-12-009 (“Systems Biology approaches in HIV/AIDS and Substance Use”)
2011:	Member, NIH Review Panel for HIV P01 application on HIV transmission and immunity (NIAID) SEP/SRG 2011/01 ZAI1 RB-A (J2) 1 meeting (Jan 2011)
2011:	Member, NIH Review Panel for PAR 10-161 “Integrated Preclinical/Clinical AIDS Vaccine Development Program” (IPCAVD) panel ZAI1-RRS-A-M1 (March 2011)
2011:	**Chair**, NIH Review Panel for HIV P01 application on HIV transmission and immunity (NIAID) SEP/SRG 2011/01 ZAI1 RB-A (J2) 1 meeting (Aug 2011)
2011-pres.:	Member, Scientific Advisory Board (SAB), University of Buffalo NIH Fogarty International Center, AIDS International Training and Research Program (AITRP).
2011-2017:	Member, External Advisory Committee (EAC), NIH T32 Program, “Training in Animal Models of Inflammation", Pennsylvania State University (PI: Pam Hankey); this T32 grant was funded in 2011. Site visited PSU in 2012.
2011:	Member, NIH Review Panel for HIVRAD RFA (HIV Vaccine Research and Design Program) (November 2011)
2011:	**Chair**, NIH Special Emphasis Panel for NIDA RFA DA-12-009 (“Systems Biology approaches in HIV/AIDS and Substance Use”) (November 2011)
2011:	*Ad hoc* reviewer for the United States-Israel Binational Science Foundation (BSF) (*http://www.bsf.org.il*)
2012:	Member and **Co-Chair**, NIH Special Emphasis Panel (SEP) Study Section for Member Conflict applications for the NeuroAIDS and Other End-Organ Diseases (NAED) Study Section within the AIDS and Related Research IRG (Feb 2012)
2012:	Member, NIH Review Panel for PAR-10-161: Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) (March 2012)
2012:	**Chair**, NIH Review Panel NIAID “Investigator Initiated Program Project Applications (PO1)” special Emphasis Panel ZAI1-MM-I-S1 (May 2012)
2012:	Member, NIH Review Panel for HIVRAD RFA (HIV Vaccine Research and Design Program) (September 2012)
2012:	Member of 2 person external review committee for the Department of Molecular Microbiology and Immunology at St. Louis University School of Medicine (October 2012)
2012:	Member and **Alternate Chair**, NIH Special Emphasis Panel: ZRG1 AARR-C 22 AIDS Fellowships Special Emphasis Panel (November 2012)
2012-2021:	Member, Scientific Advisory Board, Oyagen Inc. (UR startup company, focused on development of novel HIV therapeutics; founder - Harold Smith, Ph.D.)
2013:	*Ad hoc* member, NIH CSR Study Section VACC (Vaccine) (March 2013)
2013:	Member, NIH Review Panel for NIMH R25 and T32 HIV/AIDS Training

	Grant applications (PAR-12-273, PA-11-184) (April 2013)
2013:	**Chair**, NIH Special Emphasis Panel for member conflict applications for the NeuroAIDS and other End-Organ Diseases (NAED) Study Section (April 2013) (ZRG-1 AARR-C 03)
2013:	Reviewer, Killam Prize for Health Sciences, Canada Council for the Arts (nominated Francis Plummer, who received the award in 2014)
2013:	Member, NIH Special Emphasis Panel ZMH1 ERB-M (02): "NIMH HIV/AIDS Review"
2014:	**Chair**, NIH Special Emphasis Panel for Centers for AIDS Research (CFAR) program
2014:	Member, NIH Special Emphasis Panel for HIV-focused clinical trial implementation applications (U01s; PAR-13-151)
2014-2016:	Member, External Advisory Committee (EAC), University of Minnesota Center for AIDS Research (CFAR) (was also member from 2009-2011)
2014:	Member, NIH NIDA AIDS Avant-Garde Phase II review panel.
2015-2017:	Member, Scientific Advisory Board, WavoDyne Therapeutics (UR startup company, focussed on development of MLK3 inhibitors for treatment of neurocognitive disorders)
2015-2018:	**Permanent Member and Alternate Chair**, NAED (NeuroAIDS and other End-organ Diseases Study Section [NAED]) Study Section, NIH Center for Scientific Review. *NAED was dissolved in 2018, and I was reassigned to the HIVD Study Section (below)*
2015:	**Co-Chair**, NIH Special Emphasis Panel for AIDS Research Centers on Mental Health and HIV/AIDS (P30)
2015:	*Nominated for New York State Faculty Development and Technology Transfer Advisory Committee.*
2017-2018:	Member, inter-institutional Task Force to develop a new Therapeutic Discovery Institute in Western New York. *This resulted in the formation of the Empire Discovery Institute (EDI), a new partnership between the UR, the State University of New York at Buffalo, and the Roswell Park Cancer Institute to accelerate the process of bringing new drugs to the market. EDI, founded in 2018, is a stand-alone 501(c)(3) entity with $35M in support from New York State to move new discoveries from the lab into early stage clinical trials.*
2017:	Reviewer, Washington University Cancer Center, SPORE in Pancreatic Cancer Developmental Research Program
2017-pres.:	Member, Scientific Advisory Board, Vaccitech Limited (Oxford University vaccine startup company). *Vaccitech's chimpanzee adenovirus-vectored COVID-19 vaccine was licensed by Astra-Zeneca in 2020, and advanced into Phase III trials (and large scale production) under the auspices of Operation WarpSpeed.*
2018:	Reviewer, NYS Center of Excellence in Bioinformatics & Life Sciences Center, University at Buffalo
2018-2021:	**Permanent Member**, HIV Immunopathogenesis and Vaccine Development (HIVD) Study Section, NIH Center for Scientific Review.

2019-pres.:	Member, Life Sciences Advisory Board, Empire State Development, New York State.
2020:	Member, Advisory Committee, Sanford Lorraine Cross Award, Sanford Health, SD. *($1M prize, offered biannually for a pioneering medical breakthrough)*
2020:	Member, NIH Review panel for Emergency COVID-19 grant awards (R01, R21)
2020-2023:	Member, Scientific Advisory Board, SenseiBio (SNSE). *Cancer vaccine company, using bacteriophage technology.*
2021-pres.:	Member, NIH ACTG Executive Committee (AEC); *role: CTU PI/CRS Leader At Large*
2021:	Grant reviewer, Science Foundation Ireland (SFI) Frontiers for the Future Awards Programme
2021-pres.:	Board Member, NeuroCuresNY *(this is a not-for-profit foundation that administers a $5 million grant from New York State Empire Development Corporation. See preliminary website: https://projects.invisionapp.com/share/2DZT9XL5Q7X#/screens)*

C. Research Activities

1. Research Projects in Progress; Pending Grant Applications

See Research Biography later in this document

Funding agency = National Institutes of Health (NIH), unless otherwise stated

Pending Grant Applications:

NIH SBIR submission (Terry Bowlin PI, Microbiotix, Inc)

Development of filociclovir to treat pediatric adenovirus infections

Period: 04/01/24 – 03/31/27

Total costs: $95,000 total costs to UR ($61,688 direct costs) in Years 1 and 2

Role: PI of UR subcontract

2. Research Grants Obtained

Active Grants:

Principle Investigator (or MPI): Clinical Research Grants

2UM1AI069511-15 (Keefer*, Dewhurst; MPIs)

University of Rochester HIV/AIDS Clinical Trials Unit

Dates: 12/1/20 – 11/30/27

Annual Costs $1,185,899 (DC), $1,818,453 (Total)**

Project Costs $8,730,052 (DC), $13,386,627 (total)

Role: MPI (4.2 Cal)

**: Communicating MPI*

***: There are substantial additional costs above this base, including major funding for COVID vaccine trials*

Principle Investigator: Training Grants

2 K12 GM106997-06 (Dewhurst*, Buckley**; MPIs)

IRACDA at Rochester Partnership to Advance Research and Academic Careers in Deaf Scholars

Period: 08/01/21 – 06/30/26

Annual Direct costs: $1,067,709; Total Project direct costs (5 years): $5.338,545
Annual Total costs: $1,145,594; Total Project costs (5 years): $5,727,970
Role: Communicating MPI (0.6 Cal)
**: Communicating MPI; **: President, National Technical Institute for the Deaf (NTID)*

Co-Investigator

R01 DA054534 (Goldman, PI)
A Dual Chimeric Human Astroglial-Microglial Model of HIV and HAND
Period: 07/01/20-06/30/26
Annual direct costs: $452,691 ($100,000 per year to Dewhurst Lab)
Role: Coinvestigator (1.2 Cal)

R61 AI167035-01 (Miller, PI)
Paper-based HIV self test
Period: 01/25/22 – 12/31/24
Total costs: $1,326,253
Role: Coinvestigator (0.24 Cal)

Funded Awards to Mentored Personnel

R16 Application (Nitesh Kunda, PI - St. John's University)
R16 award mechanism = Support for Research Excellence – First Independent Research
Design and development of a novel, thermostable, and inhalable dry powder COVID-19 vaccine
Period: 2022-2027
Role: Faculty mentor (no supported effort)

Previous Grant Support (Extramural only)

Principal Investigator

American Foundation for AIDS Research (AmFAR)
Scholarship award 700081-RF
Period: 7/1/88 - 6/30/91
Total costs: $85,653

NIH RO1 AI31342
Characterization of SIV LTR
Period: 8/1/91 - 5/31/96
Total costs: $850,105

NIH KO4 AI01240 (RCDA)
Pathogenesis of, and therapy for, primate lentiviruses
Period: 06/01/94 - 05/31/99
Total costs: $335,239

NIH RO1 AI34231-01A3
HHV-6 vectors for AIDS therapy
Period: 06/01/94 - 02/28/98
Total costs: $490,624

NIH R21 AI34231
HHV-6 and HHV-7 vectors for AIDS therapy
Period: 05/01/98 - 04/30/99
Total costs: $142,940
(single year extension of the above NIH R01 award)

NIH RO1 AI39397
Immunopathology of acute SIV infection
Period: 04/01/96 - 03/30/99
Total costs: $885,705

NIH PO1 MH57556
Neuroprotection through inhibition of oxidative stress
L. Epstein - Program PI. SD - PI, Project 1.
Period: 04/01/97 - 03/31/01
Total costs: $2,514,744

NIH R21 AI44362
Targeted DNA delivery for HIV vaccine development
Period: 9/30/98 - 09/29/01
Total costs: $432,100

NIH R21 AI46259-01A1
Cytomegalovirus vectors for HIV vaccine development
Period: 9/30/99 – 8/31/01

Total: $462,535

NIH R21-DK55562-01A1
Novel systems for CNS gene therapy
Period: 2/15/00 – 1/31/02.
Total costs: $317,676

US Army DAMD1-99-1-9361
Selective DNA delivery to breast cancer cells
Period: 06/01/99 - 05/31/02
Total costs: $330,983

NIH/NIAID R21 AI49804
HSV amplicon vectors for HIV vaccine development
T. Evans, PI (UC-Davis). SD – CoPI (PI, UR subcontract).
Period: 10/1/01 – 9/30/04
Total costs: $500,000

US Army/DOD DAMD17-01-1-0385
Novel diagnostic reagents for aggressive breast cancer
SD - PI (took over from Shohei Koide, after he left UR).
Period: 4/1/01 – 3/31/04
Total costs: $478,500

NIH RO1 NS40315-01
Disregulation of neuronal GSK-3 beta by PAF
Period: 7/1/00 – 6/30/04
Total costs: $1,125,000

US Army/DOD DAMD 17-01-1-0384
Dendritic cell-targeted phage vectors for breast cancer vaccine development
Period: 6/1/01 - 5/31/04
Total costs: $478,500

NIH R21 AI49102
Lentivirus attenuation through high fidelity replication
Period: 6/8/01 - 5/30/06
Total costs: $491,015

NIH RO1 DE14194
Salivary gland adaptations of human herpesvirus (HHV)-7

Period: 7/1/01 – 2/28/07
Total costs: $1,595,000

NIH R21 AI058791
Bacteriophage gene transfer for HIV vaccine development
Period: 1/1/05 – 8/31/07
Total costs: $468,000

NIH R21 AI074351
Overcoming low HIV-1 envelope spike immunogenicity by high density display
Period: 6/15/07 – 5/31/10
Total costs: $423,500

DOD grant W81XWH-07-10376
New conditionally replicating adenovirus vectors for breast cancer therapy
SD - PI, 10%; Baek Kim - CoPI
Period: 9/1/07 – 1/31/11
Total costs: $606,302

NIH R21 AI073579-01
Lambda phage as a scaffold for influenza vaccination
Period: 11/1/07 – 10/31/10
Total costs: $423,500

NIH P30 AI078498
University of Rochester Developmental Center for AIDS Research (D-CFAR)
Period: 05/01/08 – 04/30/13*.
**: Subsequently renewed as a full CFAR*
Total costs: $5,094,699[#]
([#]: These costs included several competitively awarded supplements to the base grant)

NIH R21 AI087149-01A1
Use of Discontinuous Peptide Display for Generation of HIV Antigen Mimics
Period: 3/1/10 – 2/28/2012
Total costs: $422,167

JDRF Grant Number: 17-2010-795
DLK/MLK Inhibitors for the Treatment of Diabetic Neuropathy
Period: 9/1/10 – 2/28/12
Total costs: $290,985

NIH R01AI084111-01 *(ARRA award)*
Transmission-blocking vaccine for HIV-1
S. Dewhurst – CoPI; R. Rose – CoPI
Period: 8/14/09 – 7/31/2011
Total costs: $916,778 plus an additional supplement award of $151,983

Liquidia, LLC
Sublingual Immunization with nanoparticle-based vaccines for HIV-1 and RSV
Period: 6/15/12 – 6/31/13
Total costs: $74,998

California HIV/AIDS Research Program (CHRP) Award ID 188106
Developing inhibitors of SEVI-enhanced transmission of HIV
Jerry Yang – PI (UC San Diego); S. Dewhurst – CoPI (PI, UR subcontract)
Period: 9/1/2011 – 8/31/2013
Total costs: $172,500 (UR total costs: $62,500)

Regeneron Pharmaceuticals
UR-Regeneron Collaboration on Vaccine-Induced Antibody Responses in Velocimmune Mice
Period: 3/31/13 – 3/31/14
Total costs: $186,859

NIH R01 DA026325-01 (Dewhurst)
Cerebrovascular mechanisms in methamphetamine mediated exacerbation of neuroAIDS
Period: 9/30/08 - 5/31/15 (final year was a no-cost extension)
Total costs: $1,700,000

NIH R21 AI112717 (Dewhurst)
Enhanced Live Attenuated Influenza Virus With Improved Safety and Immunogenicity
Period: 7/1/14 – 6/30/16
Total costs: $440,300

Chimerix Research Contract (Dewhurst)
Inhibition of adenovirus DNA polymerase and viral replication by cidofovir diphosphate
Period: 12/1/15 – 2/28/18
Total costs: $121,183 ($78,947 direct costs)

NIAID Services Agreement (Dewhurst)
Evaluation of a Modified Live Attenuated Influenza Virus Vaccine Against Heterologous Influenza Virus Challenge in Mice

Period: 5/1/16 – 8/31/16
Total costs: N/A *(no cost evaluation of the breadth of protection provided by a LAIV vaccine from the University of Rochester against challenge with influenza A/California/04/2009 (H1N1) and influenza A/Anhui/1/2013 (H7N9))*

NIH R33 AI094511 (Dewhurst)
The Semen Enhancer of HIV Infection as a Novel Microbicide Target
Period: 5/1/13 – 3/31/18
Total Costs: $1,101,593

- This application was selected by NIH as an example of an outstanding application for posting to the NIAID Research Funding Web site at http://funding.niaid.nih.gov/researchfunding/grant/pages/appsamples.aspx

Grant #06012020 (Dewhurst)
Sponsor: SINTX Technologies, Inc.
Evaluation of the inhibitory activity of silicon nitride against SARS-CoV-2
Period: 06/01/20 – 06/30/21
Direct Costs: $22,933

Grant #N/A (Dewhurst)
Sponsor: TBT Group, Inc.
Assessment of a Novel Rapid Test for SARS-CoV-2 Infection
Period: 12/01/20 – 05/31/21
Direct Costs: $34,445

DOD W81XWH-17-1-0168 (Dewhurst)
Development of a New, More Effective Live-Attenuated Influenza Vaccine: An Essential Platform for Future Pandemic Protection
Period: 6/1/17 – 8/31/21
Total costs: $1,613,357

MPI or CoPI (Multiple PI Role, as formally defined by NIH)

NIH R21DE019302-01
Radioprotection by targeted siRNA delivery to salivary gland
SD - CoPI; Catherine Ovitt - CoPI
Period: 08/01/08 - 7/30/2011
Total costs: $429,000

UR University Research Award (Martínez-Sobrido, Dewhurst, Turner = PIs)

Effect of influenza virus RNA secondary structure on the host innate response to infection and virus replication
Period: 7/1/14 – 6/30/15
Total costs: $75,000

NIH R44 MH093270 (MPI) (PI: Val Goodfellow, Califia Bio; UR subcontract PI: SD)
Inhibition of HIV-Induced Synaptodendritic Damage
Period: 04/15/13 – 04/14/16 (last year was a no-cost extension)
Total costs: $1,107,507 (total UR costs: $300,924)

OT2 HD107553 (MPI) (Foxe*, Zand, Dewhurst; MPIs)
COV-IDD: Testing for COVID-19 in high risk children with intellectual and developmental disabilities
Period: 04/15/21 – 03/31/24
Total costs: $4,000,000
**: Communicating MPI*

Principle Investigator: Center Grants

NIH P30 AI104876 (Dewhurst)
University of Rochester Center for AIDS Research (CFAR)
Period: 05/01/08* – 04/30/20**
**: The first 5 years of this award was as a "Developmental CFAR"*
Total costs (2013-2019): $7,480,030
**: The final funded year was a one-year bridging award at $750k in total costs.

Principle Investigator: Infrastructure Grants

NYSTEM (New York State Stem Cell Science) Award #: N09S-001 (Dewhurst)
Upstate Stem Cell cGMP Facility
Period: 8/1/2011 – 7/31/2015
Total costs: $3,331,362

Principle Investigator, Training Awards and Similar Awards

NSF #9986712
REU Site Program in Cellular and Molecular Biology at Rochester

Period: 5/1/03 - 4/30/07
Total costs: $155,779

NIH R25 GM64133 *(NIH PREP program)*
Research and Education in Microbiology & Immunology
Period: 9/1/02 – 8/31/07*
Total costs: $1,734,175
**: Edith Lord took over this program, which has been successfully renewed multiple times. It is now directed by Jacques Robert and Elaine Smolock, as a new grant under the NIH PREP program,*

NIH T32 AI49815
Training in HIV–1 replication and pathogenesis
Period: 07/01/01 – 06/30/16*
Total costs: $819,678 (2001-2006); $803,908 (2006-2011); $891,188 (2011-2016)
**: SD PI when this award was competitively renewed in 2011, and facilitated Sanjay Maggirwar's successful renewal of the grant in 2016*

NIH DP7 DE024857 (Dewhurst - MPI [communicating]; Tracey Baas, Sarah Peyré - MPIs)
URBEST: The University of Rochester BEST Training Program
Period: 09/1/2014 – 08/31/2021
Total costs: $1,904,674

NIH K12GM106997-01A1 (MPI: Dewhurst and Doolittle, RIT)
Rochester Partnership to Advance Research and Academic Careers in Deaf Scholars
Period: 7/1/15 – 6/30/21
Total costs: $3,964,272 ($401,094 direct costs and $431,338 total costs in year 1)
A competing renewal was successfully funded in 2021

NIH 1T32AI118689-01 (Dewhurst)
Infection and Immunity: The Pathogenesis of Host-Microbe Interactions
Period: 7/1/15 – 6/30/21*
Total costs: $1,159,240 ($220,600 direct costs and $231,848 total costs in year 1)
**: The competing renewal was submitted with Paul Dunman as PI, and received a priority score of 10 in 2022. As a result, it was successfully refunded for another 5 years under new leadership.*

Burroughs Wellcome Foundation (MPI) (Bennett – CoPI #1; Dewhurst – CoPI #2)
Program: Institutional Program Unifying Population and Laboratory Based Sciences
Proposal Title: Infection and Immunity: From Molecules to Populations
Period: 02/02/2015 – 02/01/2023

Total costs: $2,500,000

Principle Investigator: Non-Research Grants

Gilead Sciences, Inc. Award # 05745 (Dewhurst)
Curiosity-Driven, Humanizing Portraits of HIV: A Narrative and Art-Based Communication Model to Improve Patient Care
Dates: 2/1/19 – 12/31/20
Project/Annual Costs $50,000 (DC), $50,000 (Total)

Program Projects (CoDirector/CoPI)

NIH PO1 AI056356 (PI: Mike Keefer, SD: overall CoPI and PI, Project 1)
HSV-1 Amplicon Vectors for HIV Vaccine Delivery
Period: 07/01/03 – 12/31/07
Total costs: $12,570,427

NIH PO1 MH064570 (PI: Handy Gelbard; SD, overall CoPI and PI, Project 1)
Targeted Neuroprotection for HIV-1 Associated Dementia
Period: 10/01/01 – 09/30/05
Total costs: $6,000,000

NIH 2PO1 MH064570 (PI: Handy Gelbard; SD, overall CoPI and PI, Core C)
Novel Adjunctive Therapies for NeuroAIDS
Period: 9/19/06 – 7/31/10
Total costs: $5,839,383

NIH 3PO1 MH064570 (Handy Gelbard)
Novel Adjunctive Therapies for NeuroAIDS
SD – overall PPG CoPI ; Coinv, Projects 1 and 2
Period: 9/30/10 – 5/31/16* (final year was a no-cost extension)
Total costs: $6,700,261

Other Co-PI

NIH S11 NS 43499 (PI: Yuanan Lu, U-Hawaii; SD, overall CoPI)
Development of gene transfer approaches for neuroAIDS
Period: 9/1/02 – 8/31/07
Total costs: $1,500,000 (UR total costs: $637,165)

Co-Investigator
PIs on these awards are/were UR faculty, unless otherwise indicated

NIH R01 NS37738 (Leon Epstein)
HIV-1 induced BBB damage in human neural xenografts
Period: 7/1/96 - 6/31/99
Total costs: $1,091,139

NIH R21 DA14950 (Jean Bidlack)
Opioid binding to U51: A human herpes virus protein
Period: 10/1/01 – 9/30/03
Total costs: $319,000

NIH RO1 MH56838 (Handy Gelbard)
Role of PAF in HIV-1 neuropathogenesis
Period: 06/01/00 - 04/30/04
Total costs: $1,141,259

R21 AA13882-01 (Rich Miller)
Placenta: Ethanol and HIV-1
Period: 9/1/02 – 8/31/05
Total costs: $450,000

NIH R01 AI49781 (Baek Kim)
Replicational fidelity and lentiviral pathogenesis
Period: 9/1/02 – 8/31/05
Total costs: $450,000

NIH R21 AI058774 (Baek Kim)
HIV-1 Vpr induced dNTP biosynthesis and DNA gap repair
Period: 4/1/04 – 3/31/07
Total costs: $551,250

NIH R21 MH071176 (Handy Gelbard)
Compartmentalized Cultures To Model NeuroAIDS
Period: 3/1/04 – 2/28/06
Total costs: $472,500

NIH R21 AI058789 (Harold Smith)
Base deamination by CEM15 suppresses HIV-1 infectivity
Period: 10/1/04 – 9/31/06
Total costs: $472,500

National MS Society, Collaborative MS Research Center grant (Ben Segal)
University of Rochester Collaborative MS Research Center
Period: 3/1/06 - 2/28/11
Total costs: $750,000
Terminated 6/30/07 when Dr. Segal left UR to join U-Michigan.

RO1 HD044430 (Caroline Hall)
Congenital HHV6 Infection: Characteristics and Outcomes
Period: 4/1/03 – 3/31/08
Total costs: $3,700,951

NIH R21 CA122213 (Baek Kim)
Novel oncolytic adenovirus for pancreatic cancer therapy
Period: 4/3/07 – 3/31/10
Total costs: $429,000

NIH 2R01 AI49781 (Baek Kim)
Replication Fidelity and Lentivirus Pathogenesis
Period: 1/1/07 - 12/30/11
Total costs: $1,732,000

NIH 3R01 AI049781 (Baek Kim)
Replicational Fidelity and Lentiviral Pathogenesis
Period: 4/1/12 – 3/31/17
Total costs: $1,545,000
Dr. Kim left UR for Emory in 2013. My role on this award was terminated at that time.

R01 AI083115 (Ha Youn Lee)
Simulator for Primary HIV Replication and Evolution
Period: 7/1/09 - 6/31/13

Total costs $1,530,240
Dr. Lee left UR for USC in 2012. My role on this award was terminated at that time.

NIH R43MH093270 (Val Goodfellow, Califia Bio, San Diego)
Non-Type 1 Inhibitors of HIV-1 Induced Synaptodendritric Damage
Period: 3/15/11 – 3/14/12
Total costs: $255,293 (Total UR costs: $101,357)

NIH R01 AI077401 (Baek Kim)
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
Period: 1/1/09 – 12/31/13
Total costs $1,236,000
Dr. Kim left UR for Emory in 2013. My role on this award was terminated at that time.

NIH DP4 GM096850 (Vivian Lewis)
Researcher Resilience through Multidimensional Mentoring
Period: 9/30/2010 – 9/29/2013
Total costs: $1,868,459

DHHS Contract HHS N2662007 00008C (overall PI: John Treanor; Project 5 PI: Toru Takimoto)
New York Influenza Center of Excellence (NYICE)
Period: 3/30/07 – 3/29/14
Total costs: $26,021,525

NYSTEM Consortium Proposal, N11C-012 (Sally Temple, New York Neuroscience Institute)
Retinal Stem Cell Consortium
SD – PI, UR subcontract
Period: 03/01/13 – 02/28/18
Total costs (UR only): $941,859

NYSTEM Consortium Proposal, N11C-012 (Burk Jubelt, SUNY Upstate)
Oligodendrocyte progenitor cell delivery for restoration of function in multiple sclerosis
Steve Goldman UR PI; SD – Lead, UR cGMP subcontract
Project Period: 3/1/2013-2/28/2018
Total costs (UR only): $5,278,253 ($2,623,202 for GMP studies)

NIH R01MH104147 (Gelbard)
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
SD – CoInvestigator
Period: 07/16/2014 – 06/30/19

Total costs: $3,621,750

CEIRS Research Project Proposal: Pandemic Supplement (Martínez-Sobrido)
The role of the avian H9N2 polymerase in efficient mammalian viral replication
SD – CoInvestigator
Period: 4/1/15 – 3/31/19
Total annual direct costs: $120,000

NIH R01 GM117005 (Kielkopf)
Structural Control of Human CoFactors for Retroviral Gene Expression
SD – CoInvestigator
Period: 03/01/2016 – 02/29/2020
Annual Direct Costs: $173,259

NIH R21 AI143494 (Miller)
Targeting CCR5 FrameShifting with Synthetic Molecules
SD – CoInvestigator
Period: 01/3/19-12/31/20
Annual Direct Costs: $125,000

U01 EY030581 (Stern, PI)
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD
SD – CoInvestigator
Period: 09/01/19 – 06/30/21 (NCE)
Annual Direct Costs: $150,920

NIH R01 GM123864 (Wedekind)
Title: Cyclic Peptide Inhibitors of HIV-1 Proliferation
SD – CoInvestigator
Period: 8/1/18 – 7/31/21
Total costs: $1,939,490

P50HD103536-03S1 (Foxe, PI)
Administrative Supplement to University of Rochester Intellectual and Developmental Disabilities (IDD) Research Center, for COVID antibody testing in children with IDD.
SD: CoInvestigator
Period: 08/23/22 - 09/30/23
Total costs: $138,573

Awards *Mentored* by S. Dewhurst

NIH F32 AI08894
Analysis of an acutely lethal isolate of SIV
PI: Sheila Dollard (postdoctoral trainee)
Period: 6/1/93 - 5/31/95
Total costs: $138,991

NIH F31 GM17802
NF-κB and neuropathogenesis of SIV infection
PI: Shekema Hodge (predoctoral trainee)
Period: 9/15/95 - 6/1/99
Total costs: $128,695

James P. Wilmot Foundation, Cancer Research Fellowship
Microglial responses to brain tumors
PI: Steve Fine (postdoctoral trainee)
Period: 7/1/96 - 6/30/99
Total costs: $161,129

NIH KO8 AI01419
Role of astrocytes in HIV-1 neuropathogenesis
PI: Steve Fine (postdoctoral trainee)
Period: 7/1/96 - 6/30/99
Total costs: $271,547

NIH KO8 AI01586
Immune cell activation by a unique lentivirus Nef allele
PI: Linda Whetter (Research Assistant Professor)
Period: 12/1/98 - 11/30/01
Total costs: $262,304

Supplement to NIH 2RO1 MH56838
Role of PAF in HIV-1 neuropathogenesis
PI: Joe Sanchez (predoctoral trainee)
Period: 10/01/00 – 4/31/02
Total costs: $93,898

NIH F31 AI/GM10536

Effect of SIVsmmPBj14 Nef in dendritic cell function
PI: Ramothea Webster (predoctoral trainee, MD/PhD)
Period: 09/01/00 - 09/30/03
Total costs: $130,000

NIH F31 AI10666
Activation of GSK-3β by candidate HIV neurotoxins
PI: Servio Ramirez (predoctoral trainee)
Period: 04/15/01 – 04/14/05
Total costs: $139,264

NIH F31 AI054330
Phage vectors for HIV vaccine development
PI: Kathlyn Santos (predoctoral trainee)
Period: 02/01/03 - 01/31/07
Total costs: $154,640

Supplement to NIH RO1 DE014194
Adaptation of human herpesvirus-7 to salivary glands
PI: Ramil Sapinoro (predoctoral trainee)
Period: 8/1/02 – 2/28/07
Total costs: $201,454

Supplement to NIH PO1 AI056356-01
HSV-1 Amplicon Vectors for HIV Vaccine Delivery
PI: Cindy Duke (predoctoral trainee, MD/PhD)
Period: 5/1/04 – 12/31/07
Total costs: $201,653

Supplement to NIH T32 in Oral Biology
PI: Cristina Capella (predoctoral trainee)
Period: 9/1/06 – 8/31/11
NIDCR administratively added a new student slot to this T32 award, specifically for Cristina

NIH F31 AI071380
Modified lambda phage for HIV vaccine delivery
PI: Ketna Volcy (predoctoral trainee)
Period: 4/1/07 – 8/31/09
Total costs: $133,435

Supplement to NIH R01DA026325 (summer undergraduate research)
"Cerebrovascular Mechanisms in methamphetamine-mediated exacerbation of neuroAIDS"
PI: Tenée Lopez (University of Houston)
Period: 5/31/11 – 8/6/11
Total costs: $8,824

Creative and Novel Ideas in HIV Research Award (CNIHR)
Probing the Structure and Function of Semen Enhancer of HIV Infection
PI: Brad Nilsson
Period: 08/01/2010-07/31/2012
Total costs: $461,439

Supplement to NIH R01 DA026325
Cerebrovascular Mechanisms in methamphetamine-mediated exacerbation of neuroAIDS
PI: Jharon Silva (predoctoral trainee, MD/PhD)
Period: 9/1/10 – 6/31/13
Total Costs: $114,592

UR CTSA KL2 Scholar Award
Attenuating Functional Decline in HIV-Infected Older Adults With Central Obesity
PI: Krupa Shah
Period: 07/01/2012-07/31/2014
Total costs: $150,000

Creative and Novel Ideas in HIV Research Award (CNIHR)
Apoptotic cell clearance signaling and HIV-associated inflammation
PI: Michael "Rusty" Elliott
Period: 08/01/2012-07/31/2014
Total costs: $450,000

UR Technology Development Fund application
Development of a modified Live Attenuated Influenza Virus Vaccine
PI: Andy Cox (MD/PhD trainee)
Period: 04/01/14 – 03/31/15
Total costs: $35,000

K23 AG043319-01A1
Feasibility of an Exercise Intervention in HIV+ Older Adults with Central Obesity
PI: Krupa Shah

Period: 09/01/13 – 05/31/17
Total costs: $602,339

Awards Made to Supervised Personnel

NIH R21 AI46312
Novel approaches to dendritic cell stimulation
PI: Linda Whetter (Research Assistant Professor)
Period: 07/01/99 - 06/30/01
Total costs: $462,000

Grants on which I was a consultant or other significant contributor
The PI is or was a UR faculty member, unless otherwise indicated

NIH R01 GM049573 (Robert Bambara)
DNA Synthesis and Recombination by HIV DNA Polymerase
Period: 4/1/04 – 3/31/09
Total costs: $1,078,000

NIH R01 MH056838 (Handy Gelbard)
Platelet Activating Factor, Synaptic Failure & NeuroAIDS
Period: 9/1/04 – 8/31/09
Total costs: $1,850,625

NIH R01 MH077789 (Handy Gelbard)
Non-invasive photoconductive model for neuroAIDS
Period: 7/1/06 – 6/31/10
Total costs: $1,700,000

NIH R01 DE08921 (Jim Melvin)
Physiology of Mucous-Secreting Salivary Glands
Period: 9/1/04 – 8/31/09
Total costs: $1,950,350

NIH UL1 RR024160; 1 KL2 RR024136; 1 TL1 RR024135 (Tom Pearson)
The University of Rochester's Clinical and Translational Science Institute
SD roles:

- Member, Integrated Approach/Governance Key Function

- Member, Research Education, Training , and Career Development

Period: 9/30/06 - 6/30/11
Total costs: approx. $31,000,000

NIH 2R25GM064133 (Edith Lord)
Research and Education in Microbiology & Immunology
Period: 12/1/08 - 11/30/12
Total costs: $1,192,448

NIH 2UM1 AI069511 (Mike Keefer)
University of Rochester HIV/AIDS Clinical Trials Unit
Period: 12/10/13 - 11/30/20
Total costs: approx. $12,000,000
Made a major contribution to writing this proposal (0% FTE on the grant)

Other Awards (Awards to Codevax, for which I served as President)

NIH R43 AI085844
Anti-Autolysin Passive Immunity for MRSA Osteomyelitis
Overall PI: John Daiss; UR subcontract PI: Eddie Schwarz
Period: 7/1/10 – 6/30/11
Total costs: $326,193

D. Presentations

Since 2010 only

Extramural Research Seminars

2010: **John Wiley Jones Distinguished Speaker** for the College of Science at the Rochester Institute of Technology

2010: Invited seminar, SUNY Upstate Medical University, Syracuse, NY

2010: Invited seminar, Boston University

2011: Invited seminar, Regeneron (with Inaki Sanz, James Kobie, Mark Sullivan, Andrea Bottaro)

2011: Invited seminar, Temple University

2012: Invited seminar, Regeneron (with James Kobie, Mark Sullivan)

2013: Invited seminar on the NIGMS Structural Biology Centers for HIV/AIDS Research, National CFAR Directors meeting (Miami, FL)

2014: Invited seminar, Rochester Institute of Technology (RIT). "World of Wonder" (WoW) seminar series (RIT-UR Rochester Bridges to the Doctorate for Deaf and Hard of Hearing Students).

2015: **Presidential Visiting Scholar**, Temple University.

2015: **Keynote Speaker**, Dall 2015 Graduate Studies Convocation Ceremony, University of Nebraska Medical Center, Omaha, NE.

2016: Invited seminar, University of Utah

2018: Invited seminar, Rochester Institute of Technology (RIT)/National Technical Institute for the Deaf (NTID). RISE seminar series (for deaf and hard of hearing students).

2019: Invited seminar, Michigan State University, East Lansing, MI

2019: Invited seminar, Gilead Sciences, Foster City, CA "*Destigmatising through Humanising*" (joint presentation with URMC Artist-in-Residence, Charmaine Wheatley)

2022: Invited lecture, BURROW (Buffalo Upstate Rochester: Research Out Western NY) Medical Scientist Training Program (MSTP) Conference, Rochester NY, October 2022 (Presentation: Management 101 for Physician-Scientists)

Intramural Presentations

2010: Biology Department seminar

2010: **Commencement speaker**, UR SMD M.S. commencement ceremony

2010: Invited seminar, Community Advisory Board (CAB), HIV Clinical Trials Unit (CTU), UR (Community Seminar)

2010: Invited presentation, Upward Bound summer program, UR *(for minority high school students interested in college)*

2010: Life Sciences Learning Center (LSLC): *presentation to high school class from Ganonda*

2010:	Presenter/Participant: Faculty Development Program on "Meeting the Challenge of Academic Careers: Launching Research and Scholarly Agendas" (Office of the Provost)
2010:	Invited speaker, GlobeMed and Public Health Undergraduate Council World AIDS Day event, UR River Campus
2011:	Presentation on "Mentors and Mentees" *(part of noon luncheon series on Diversity, Sponsored by the Office of the Associate Dean for Diversity, URMC)*
2011:	Presentation on "Productivity-Based Compensation" to URSMD leadership
2011:	Discussant, Roundtable Discussion with Stephen Bloch of Canaan Partners investment group
2012:	Presentation on "Research Incentives" to URSMD leadership
2012:	Presenter, URSMD Core Imaging Day: "Analysis of HIV-Associated Cerebrovascular Pathology in a Murine Model System Using Laser Doppler Flowmetry and Multiphoton Imaging"
2012:	Presenter, Second Science Social - Friday seminar series, URSMD. May. "Why does semen contain amyloid fibrils? And what do they have to do with HIV transmission?"
2012:	Presenter, AOTrauma Clinical Priority Program external site visit: (1) UR cGMP Stem Cell Facility; (2) Opportunities for Collaboration between AOT CPP and the UR Department of Microbiology and Immunology
2012:	Presenter, UR Cardiovascular Research Institute (CVRI): "Cerebrovascular disregulation caused by HIV-associated neuroinflammation"
2013:	Presenter, RIPS (Research In Progress, Immunology): Feb: "Why does semen contain amyloid fibrils? And what do they have to do with HIV transmission?"
2013:	Presenter and Panel Member, Pathfinder Mentoring Workshop
2014:	Presenter, Introduction to Medical Center Leadership Faculty Development Series: "Leadership in Research"
2014:	Presenter, Dept. of Ob/Gyn Research Workshop: "Why Does Semen Contain Amyloid Fibrils?"
2015:	Presenter, URBEST Career Story Q&A Seminar Series. See also related blog post: http://blogs.democratandchronicle.com/rocnext/2015/01/17/what-i-love-about-my-job/
2015:	Co-Presenter with David Williams, UR Faculty Senate: "Strategies for Success in Sponsored Research in a Time of Reduced Funding"
2015:	Presenter, *Managing Staff*, URMC Junior Faculty Academic Core Curriculum
2016:	Presenter, Medical Center – River Campus collaborations, URMC Medical Faculty Council
2016, 2017:	Presenter, *Managing People*, Developing from Within: internal leadership academy for Female Associate Professors at URMC
2017:	Invited Presenter, IND 436 CTSI Seminar Series: "*Self Confidence*"

2017-pres.: **Introductory Speaker**, Graduate (Ph.D.) Student Interview Days, URMC

2020: Second Friday Science Social Seminar Series: "*Art Meets Science: Curiosity and Discovery*", URMC (joint presentation with URMC Artist-in-Residence, Charmaine Wheatley)

2021: Invited Presenter, *Building and Managing an Effective Research Program.* URSMD JFBRA (Junior Faculty in Biomedical Research Association)

2022: Invited Lecture: "*Art Reducing Stigma: Humanizing HIV*", UR Memorial Art Gallery (joint presentation with UR Golisano Children's Hospital Artist-in-Residence, Charmaine Wheatley). *This presentation was in conjunction with the MAG's AIDS Posters Exhibit, Up Against the Wall.*

2022: Invited Lecture: "*HIV/AIDS: From the Discovery of AIDS to Living with HIV in the Time of COVID-19*", UR Memorial Art Gallery (joint presentation with UR alum and discoverer of AIDS, Michael Gottlieb). *This presentation was in conjunction with the MAG's AIDS Posters Exhibit, Up Against the Wall.*

2024: Invited Lecture: *"The History of Vaccines and Anti-Vaxxers,",* annual retreat of the UR Clinical Trials Unit (CTU) Community Advisory Board (CAB), Rochester Rainbow Union, Rochester, NY

Extramural – Private Sector Partnering, Advancement/Alumni, Other (non-Research)

2011: Presenter on infectious diseases and vaccines to Pfizer leadership (part of UR leadership teleconference team w. Dean Taubman, Peter Robinson, Scott Steele and Steve Feldon).

2011: Presenter, Rochester Innovation Forum. *Presentation on URMC technologies to Rochester area VCs and UR alumni and friends with expertise in technology transfer and/or enterprise formation, including investors in early stage ideas (part of UR leadership team w. Provost Kuncl, Dean Taubman, Advancement team) (PAETEC Rochester)*

2011: Presenter, Boston Innovation Forum. *Presentation on URMC technologies to Boston area VCs and UR alumni and friends with expertise in technology transfer and/or enterprise formation, including investors in early stage ideas (part of UR leadership team w. Provost Kuncl, Dean Taubman, Advancement team) (Boston MA).*

2011: Invited seminar, Liquidia *(biotech developing nanoparticle-based delivery systems and vaccines (Durham, NC). This resulted in a sponsored research collaboration.*

2011: Presenter, San Francisco Innovation Forum. *Presentation on URMC technologies to San Francisco area VCs and UR alumni and friends with expertise in technology transfer and/or enterprise formation, including investors in early stage ideas (part of UR leadership team w. Dean Clark, Advancement team) (San Francisco, CA)*

2012: Presenter, New York City Innovation Forum. *Presentation on URMC technologies to New York area VCs and UR alumni and friends with expertise in technology transfer and/or enterprise formation.*

2012: Presenter, "The University of Rochester, Excell Partners and Private Foundation: A Conversation on Novel Ways to Work Together" *(hosted by*

Nixon Peabody LLC, Rochester, NY; with Rob Clark, Senior VP of Research and Dean of the School of Engineering; Theresa Mazzullo, President of Excell Partners; Gail Norris, UR Vice Provost)

2013: Presentation to the Empire State Pride Agenda on the UR CFAR and HIV/AIDS related research programs

2013-pres.: Interviews with local media (TV, radio, print), representing the UR on various topics including: NYS efforts to support faculty recruitment and retention; research funding; the UR's biosafety committee and more.

2014: Lead Presenter, Virginia Beach Area Alumni Forum. *Presentation on URSMD research to Virginia Beach area UR alumni and friends*

2014: Lead Presenter, Boston Area Alumni Forum. *Presentation on URSMD Ph.D. programs and research to Boston area UR Ph.D. alumni and friends*

2014: Lead Presenter, San Francisco Area Alumni. *Presentations on URSMD Technology Development Fund (TDF) and new biomedical research training programs (pre- and post-doctoral) to San Francisco area UR Ph.D. alumni and friends.*

2014: Lead Presenter. *Presentation on URSMD HIV/AIDS Research Directions to Rochester area friends of the University.*

2015: Lead Presenter. *Presentation on URSMD HIV/AIDS Research Directions to New York City area alumni friends of the University*.

2015: Presenter and Session Leader, UR Board of Trustees Leadership Retreat in Amelia Island, Florida (March 2015). *Led sessions on data science and the brain and aging*.

2015: Presenter, UR Neuroscience Program Retreat. *Outlined plans for the new Del Monte Neuromedicine Institute to the UR neuroscience community.*

2015: Presenter, Webinar on HIV/AIDS for UR alumni.

2015: Presenter, UR MEL Talk (Meliora Weekend activities for UR alumni); presentation on "Improving the Influenza Vaccine"

2017: **Keynote Speaker**, inaugural March for Science and Rochester Science Expo, Rochester, NY

2017: Invited Presenter: "*At the Helm: Management 101 for Physician-Scientists*", Northeast Regional Meeting of the ASPA (American Student Physicians Association). Meeting held in Rochester, NY.

2017, 2018: Presenter on UR Center for AIDS Research (CFAR). *Presentations to NIH CFAR program officers, in connection with competing renewal of the UR CFAR.*

2017-2018: Presenter on Empire Discovery Institute (EDI) to multiple audiences at UR and the University of Buffalo. *EDI is a new partnership between the UR, the State University of New York at Buffalo, and the Roswell Park Cancer Institute to accelerate the process of bringing new drugs to the market. EDI is a stand-alone 501(c)(3) entity with $35M in support from New York State to move new discoveries from the lab into early stage clinical trials.*

2018: **Invited Panel member**, *New York Stem Cell Science: A Decade of Discoveries Generating a Future of Cures*. Organized by AMSNY

(Association of Medical Schools of New York). New York State Assembly, Albany, NY.

2018: Invited Presenter on UR research, for UR Advancement regional presentations to alumni and potential donors. New York City, Chicago.

2019: Invited Presenter on UR research, for UR Advancement regional presentations to alumni and potential donors. Atlanta (focus: globalization), New York City (focus: RNA Biology).

2020-2021: Moderator, multiple COVID-19 research forums, for UR Advancement and Alumni communities

2021: "Books Sandwiched In" presentation on: "The Doctor Who Fooled the World: Science, Deception and the War on Vaccines" by Brian Deer. *Friends & Foundation of the Rochester Public Library (FFRPL).* https://ffrpl.libraryweb.org/programs/books-sandwiched-in/

2021: Moderator, Experience Rochester panel on COVID-19 vaccines and therapeutics, at Meliora 2021, for UR Advancement and Alumni communities.

2021: Co-organizer (with Peter Robinson, Scott Steele), symposium on "*SBIR and other Resources to Support University Technology Commercialization*"

2022: Co-organizer (with Josh Farrelman, Cindy Gary and others) of the visit of the NSF Director, Sethuraman Panchanathan, to the UR campus

2021-pres.: Periodic presentations on UR research activities to UR Board of Trustees, visiting dignitaries, Rochester business community members, etc.

Extramural – Continuing Education/Meetings Attended (without presentation)

2015: Career Flexibility for Biomedical Faculty of Today and Tomorrow: A National Conference, BU Medical Campus, Boston, MA

2015: Initial conference of the Atlantic Biotechnology Innovation and Commercialization Consortium, University of Pittsburgh (Pitt, CMU, WVU, UR attending). *Goal was to develop a shared approach to technology development and commercialization.*

2017: Safe Space Part I: Foundations of Being an Ally & Safe Space Part II: Inclusive Practices for Allies, UR. *These courses are intended to provide participants with information about ways to provide safe spaces and support for Lesbian, Gay, Bisexual, Transgender (LGBT) & Allied people regarding issues they may confront in the workplace and elsewhere.*

2018: Stanford Academic cGMP Symposium, Palo Alto, CA.

2021: Participant, Enlightened Leadership In Challenging Times learning series (led by Jeff Ring, Ph.D.). *A series of six 1.5 hour meetings, two individual coaching sessions, and a final project - intended to build greater understanding and awareness among institutional leadership of issues related to equity and inclusion, and to promote institutional culture change.*

2021-2022: Member, Enlightened Leadership In Challenging Times learning community. *An ongoing institutional learning community at URSMD that*

arose from the preceding learning series, and that promotes institutional culture change toward greater equity and inclusion.

2021: Participant, U-Wisconsin Center for the Improvement of Mentored Experiences in Research (CIMER) workshop on Optimizing Mentoring Relationships at the University of Rochester (8 contact hours; 06/2021)

2021: Participant, CIMER workshop on Culturally Aware Mentoring (CAM) at the University of Rochester (6 contact hours; 10/2021)

F. Publications

Personnel under my supervision are denoted in boldface type.

This list is available online at: https://orcid.org/0000-0001-7729-7920

Original Scientific Articles

1. Casareale, D., **Dewhurst, S.,** Sonnabend, J., Sinangil, F., Purtilo, D.T., and Volsky, D.J. Prevalence of AIDS-associated retrovirus among male homosexuals at risk for AIDS in Greenwich Village. **AIDS Res**. 1:407-421, 1984.
2. Rodriquez, L., **Dewhurst, S.,** Sinangil, F., Merino, F., Godoy, G., and Volsky, D.J. Antibodies to HTLV-III/LAV among aboriginal indians in Venezuela. **Lancet** i: 1098-1100, 1985.
3. **Dewhurst, S.,** and Volsky, D.J. A simple method for the production of specific antiserum to the second nuclear antigen (EBNA-2) of Epstein-Barr virus (EBV). **J. Immunol. Meth.** 87:283-287, 1986.
4. Volsky, D.J., Rodriquez, L., **Dewhurst, S.,** Sinangil, F., Sakai, K., Merino, F., and Esparza, B. Antibodies to acquired immune deficiency syndrome (AIDS) - associated virus (HTLV-III/LAV) in Venezuelan populations. **AIDS Res.** 2:79-92, 1986.
5. Goldsmith, J.C., **Dewhurst, S.,** Hedenskog, M., Casareale, D., and Volsky, D.J. High prevalence and high titers of LAV/HTLV-III antibodies among hemophiliacs in midwestern United States. **Am. J. Med.** 81:579-583, 1986.
6. Hedenskog, M., **Dewhurst, S.,** Ludvigsen, C., Sinangil, F., Rodriquez, L., Wu, Y.T., and Volsky, D.J. Testing for antibodies to AIDS-associated retrovirus (HTLV-III/LAV) by indirect immunofluorescence: specifity, sensitivity and applications. **J. Med. Virol.** 19:325-334, 1986.
7. **Dewhurst, S.,** Stevenson, M., and Volsky, D.J. Expression of the T4 molecule (AIDS virus receptor) by human brain-derived cells. **FEBS Lett.** 213:133-137, 1987.
8. **Dewhurst, S.,** Bresser, J., Stevenson, M., Sakai, K., Evinger-Hodges, M.J., and Volsky, D.J. Susceptibility of human glial cells to infection with human immunodeficiency virus (HIV). **FEBS Lett.** 213:138-143, 1987.
9. **Dewhurst, S.,** Stevenson, M., McComb, R.D., and Volsky, D.J. Expression of glial fibrillary acidic protein in human glioma cell lines as detected by molecular hybridization. **Acta Neuropathol. (Berl.)** 73:383-386, 1987.
10. **Dewhurst, S.,** Sakai, K., Bresser, J., Stevenson, M., Evinger-Hodges, M.J. and Volsky, D.J. Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV. **J. Virol.** 61:3774-3782, 1987. PMCID: PMC255992
11. **Dewhurst, S.,** Sakai, K., Zhang, X.H., Wasiak, A., and Volsky, D.J. Establishment of human glial cell lines chronically infected with the human immunodeficiency virus (HIV). **Virology** 162:151-159, 1988.
12. Sakai, K., **Dewhurst, S.,** Ma, X., and Volsky, D.J. Heterogeneity in biological properties of infectious molecular clones of human immunodeficiency virus (HIV) simultaneously isolated from the same individual. **J. Virol.** 62:4078-4085, 1988. PMCID: PMC253838
13. **Dewhurst, S.,** Embretson, J.E., Anderson, D.C., Mullins, J.I., and Fultz, P.N. Sequence analysis and acute pathogenicity of molecularly cloned $SIV_{smmPBj14}$. **Nature** 345:636-640, 1990.

14. **I**glewski, W.J., and **Dewhurst, S.** Cellular mono(ADP-ribosyl) transferase inhibits protein synthesis. **FEBS Lett.** 283:235-238, 1991.

15. **Dewhurst, S.,** Embretson, J.E., Fultz, P.N., and Mullins, J.I. Molecular clones from a non-acutely pathogenic derivative of SIV $_{smmPBj14}$: characterization and comparison to acutely pathogenic clones. **AIDS Res. Hum. Retrovir.** 8:1179-1187, 1992.

16. **Dewhurst, S.,** Chandran, B., McIntyre, K., Schnabel, K., and Hall, C.B. Phenotypic and genetic polymorphisms among human herpesvirus-6 isolates from North American infants. **Virology** 190:490-493, 1992.

17. **Dewhurst, S.,** McIntyre, K., Schnabel, K., and Hall, C.B. Human herpesvirus-6 type-B accounts for the majority of primary HHV-6 infections in U.S. infants. **J. Clin. Microbiol.**, 31:416-418, 1993. PMCID: PMC262777

18. Krohn, K.J.E., Hakkarainen, K., Aavik, E., **Dewhurst, S.,** Sadaie, R., and Mullins, J.I. transcomplementation of SIV Rev with HTLV-I Rex. **J. Virol.** 67:5681-5684, 1993. PMCID: PMC237976

19. **Dewhurst, S., Dollard, S.C.,** Pellett, P.E., and Dambaugh, T.R. Identification of a lytic-phase origin of DNA replication in human herpesvirus 6. **J. Virol.** 67:7680-7683, 1993. PMCID: PMC238241

20. Thomson, B., **Dewhurst, S.,** and Gray, D. Structure and heterogeneity of the a sequences of human herpesvirus 6 strain Z29 U1102 and strain Z29 and identification of human telomeric sequences at the genomic termini. **J. Virol.** 68:3007-3014, 1994. PMCID: PMC236791

21. Hall, C.B., Long, C.E., Schnabel, K.C., Caserta, M.T., McIntyre, K.M., Costanzo, M.A., Knott, A., **Dewhurst, S.,** Insel, R.A., and Epstein, L.G. Human herpesvirus-6 infection in children: prospective evaluation for complications and reactivation. **N. Engl. J. Med.** 331:432-438, 1994.

22. **Dewhurst, S., Krenitsky, D.M.,** and **Dykes, C.** Human herpesvirus 6B origin: sequence diversity, requirement for two binding sites for origin-binding protein and enhanced replication from naturally occurring origin multimers. **J. Virol.** 68:6799-6803, 1994. PMCID: PMC237107

23. **Dollard, S.C., Gummuluru, R., Tsang, S., Fultz, P.N.,** and **Dewhurst, S.** Evidence for a role of nuclear factor κB (NFκB) in the unusual virulence of the PBj14 strain of simian immunodeficiency virus. **J. Virol**. 68:7800-7809, 1994. PMCID: PMC237241

24. Caserta, M., Hall, C.B., Schnabel, K., McIntyre, K., Long, C., Costanzo, M., **Dewhurst, S.,** Insel, R., and Epstein, L.G. Neuroinvasion and persistence of human herpesvirus-6 in children. **J. Infect. Dis.** 170:1586-1589, 1994.

25. Frenkel, L.M., Wagner, L., Atwood, S., Cummins, T., and **Dewhurst, S.** A specific, sensitive and rapid assay for HIV-1 pol mutations associated with resistance to zidovudine (ZDV) and didanosine (ddI). **J. Clin. Microbiol.** 33:342-347, 1995. PMCID: PMC227945

26. Talley, A.K., **Dewhurst, S.,** Perry, S., **Dollard, S.C., Gummuluru, S., Fine, S.M.,** New, D., Epstein, L.G., Gendelman, H.E., Genis, P., and Gelbard, H.A. Tumor necrosis factor alpha induces apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. **Mol. Cell. Biol.** 15:2359-2366, 1995. PMCID: PMC230464

27. Saito, Y., Sharer, L.R., **Dewhurst, S.,** Blumberg, B.M., Hall, C.B., and Epstein, L.G. Cellular localization of human herpesvirus-6 in the brains of children with AIDS encephalopathy. **J. Neurovirol.** 1:30-39, 1995.
28. Frenkel, L.M., Wagner, L., Demeter, L.M., **Dewhurst, S.,** Coombs, R.W., Murante, B.L., and Reichman, R.C. Effects of zidovudine use in pregnancy on HIV-1 resistance and vertical transmission. **Clin. Infect. Dis.** 20:1321-1326, 1995.
29. **van Loon, N., Gummuluru, S., Sherwood, D.J., Marentes, R.,** Hall, C.B., and **Dewhurst, S**. Sequential analysis of human herpesvirus 6 (HHV-6) sequences from infants and comparison of sequences from mother/infant pairs. **Clin. Infect. Dis.** 21:1017-1019, 1995.
30. Secchiero, P., Nicholas, J., **Deng, H., Xiaopeng, T., van Loon, N.**, Ruvolo, V.R., Berneman, Z.N., Reitz, M.S., and **Dewhurst, S**. Identification of human telomeric repeat motifs at the genome termini of human herpesvirus 7: structural analysis and heterogeneity. **J. Virol. 69**:8041-8045, 1995. PMCID: PMC189750
31. **Dollard, S.C.,** James, H.J., Sharer, L.R., Epstein, L.G., Gelbard, H.A., and **Dewhurst, S.** Activation of nuclear factor κB in brains from children with HIV-1 encephalitis. **Neuropathol. Appl. Neurobiol.** 21:518-528, 1995.
32. **Gummuluru, S.**, Novembre, F.J., Seshi, B., and **Dewhurst, S**. $SIV_{smmPBj14}$ induces expression of a mucosal integrin on macaque lymphocytes. **Virology** 215:97-100, 1996.
33. **Fine, S.M.**, Angel, R.A., Perry, S.W., Epstein, L.G., Rothstein, J., **Dewhurst, S**., and Gelbard, H.A. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes: implications for pathogenesis of HIV-1 dementia. **J. Biol. Chem.** 271:15303-15306, 1996.
34. **Gummuluru, S.,** Novembre, F.J., Lewis, M., Gelbard, H.A., and **Dewhurst, S**. Apoptosis correlates with immune activation in intestinal activation in lymphoid tissue from macaques acutely infected by a highly enteropathic simian immunodeficiency virus, $SIV_{smmPBj14}$. **Virology** 225:21-32, 1996.
35. **van Loon, N.V.L., Dykes, C., Deng, H.,** Dominguez, G., Nicholas, J., and **Dewhurst, S.** Identification and analysis of a lytic-phase origin of DNA replication in human herpesvirus 7. **J. Virol.** 71:3279-3284, 1997. PMCID: PMC191464
36. **Dykes, C., Chan, H., Krenitsky, D.M., and Dewhurst, S.** Stringent structural and sequence requirements of the human herpesvirus 6B lytic-phase origin of DNA replication. **J. Gen. Virol.** 78:1125-1129, 1997.
37. Krajewski, S., James, H.J., Ross, J., Blumberg, B.M., Epstein, L.G., Gendelman, H.E., **Gummuluru, S., Dewhurst, S.**, Sharer, L.R., Reed, J.C., and Gelbard, H.A. Expression of pro- and anti-apoptosis gene products in brains from paediatric patients with HIV-1 encephalitis. **Neuropath. Appl. Neurobiol.** 23:242-253, 1997.
38. Bar-Peled, O., Ben-Hur, H., Biegon, A., Groner, Y., **Dewhurst, S.**, Furata, A., and Rothstein, J.D. Distribution of glutamate transporter subtypes during human brain development. **J. Neurochem.** 69:2571-2580, 1997.
39. **Deng, H. and Dewhurst, S.** Functional identification and analysis of cis-acting sequences which mediate genome cleavage and packaging in human herpesvirus 6. **J. Virol.** 72:320-329, 1998. PMCID: PMC109379
40. Hall, C.B., Caserta, M.T., Schnabel, K.C., Long, C., Epstein, L.G., Insel, R.A., and **Dewhurst, S.** Persistence of human herpesvirus 6 (HHV6) according to site and variant: possible greater neurotropism of variant A. **Clin. Infect. Dis.** 26:132-137, 1998.

41. Bulboaca, G., **Deng, H.,** **Dewhurst, S.**, and Calos, M.P. Telomeric sequences from human herpesvirus 6 do not mediate nuclear retention of episomal DNA in human cells. **Arch. Virol.** 143:563-570, 1998.
42. Saucier, M., **Hodge, S.,** **Dewhurst, S.**, Gibson, T., Gibson, J.P., McClure, H.M., and Novembre, F.N. The tyrosine-17 residue of Nef in $SIV_{smmPBj14}$ is required for acute pathogenesis and contributes to replication in macrophages. **Virology** 244:261-272, 1998.
43. **Whetter, L.,** Novembre, F.J., Saucier, M., **Gummuluru, S.**, and **Dewhurst, S**. Costimulatory pathways in lymphocyte proliferation induced by simian immunodeficiency virus, SIVsmmPBj14. **J. Virol.** 72:6155-6158, 1998. PMCID: PMC110423
44. Perry, S.W., Dbaibo, G., Dzenko, K.A., Gendelman, H.E., Epstein, L.E., Hannan, Y., Whittaker, J.S., **Dewhurst, S.**, and Gelbard, H.A. PAF receptor activation: an initiator step in HIV-1 neuropathogenesis. **J. Biol. Chem.** 273:17660-17664, 1998.
45. New, D.R., **Maggirwar, S.B.**, Epstein, L.G., **Dewhurst, S.**, and Gelbard, H.A. HIV-1 Tat induces neuronal death via tumor necrosis factor α and activation of non-NMDA receptors by a NFκB-independent mechanism. **J. Biol. Chem.** 273:17852-17858, 1998.
46. **Hodge, S.M.,** Novembre, F.N., **Dewhurst, S.** Endogenous tumor necrosis factor-α contributes to lymphoproliferation induced by simian immunodeficiency virus variant, SIVsmmPBj14. **Immunol. Lett.** 63:49-51, 1998.
47. **Deng, S.X.**, Panahian, N., James, H., Gelbard, H.A., Federoff, H.J., **Dewhurst, S**., and Epstein, L.G. Luciferase: a sensitive and quantitative probe for blood-brain barrier disruption. **J. Neurosci. Meth.** 83:159-164, 1998.
48. Rotola, A., Ravaioli, T., Gonelli, A., **Dewhurst, S.**, Cassai, E., and Di Luca, D. U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture. **PNAS USA** 95:13911-13916, 1998. PMCID: PMC24961
49. **Maggirwar, S.M.,** Sarmiere, P.D., **Dewhurst, S.**, and Freeman, R.S. Nerve growth factor-dependent activation of NF-κB contributes to survival of sympathetic neurons. **J. Neurosci.** 18:10356-10365, 1998.
50. **Hodge, S.**, Novembre, F.J., **Whetter, L.**, Gelbard, H.A., and **Dewhurst, S.** Induction of Fas ligand expression by an acutely lethal simian immunodeficiency virus, SIVsmmPBj14. **Virology** 252:354-363, 1998.
51. **Fine, S.M., Maggirwar, S.B., Elliott, P.R.,** Epstein, L.G., Gelbard, H.A., and **Dewhurst, S.** Proteasome blockers inhibit TNF-α release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. **J. Neuroimmunol.** 95:55-64, 1999.
52. **Maggirwar, S.M.,** Tong, N., **Ramirez, S.**, Gelbard, H.A., and **Dewhurst, S.** HIV-1 Tat mediated activation of glycogen synthase kinase-3β (GSK-3β) contributes to Tat-mediated neurotoxicity. **J. Neurochem.** 73:578-586, 1999.
53. Dominguez, G., Dambaugh, T.R., Stamey, F.R., **Dewhurst, S.**, Inoue, I., and Pellett, P.E. Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. **J. Virol.** 73:8040-8052, 1999. PMCID: PMC112820
54. **Hodge, S.,** DeRosayro, J., Glenn, A., **Ojukwu, I.C.,** **Dewhurst, S.**, McClure, H.M., Bischofberger, N., Anderson, D.C., Klumpp, S.A., and Novembre, F.J. Post-inoculation PMPA treatment, but not pre-inoculation immunomodulatory therapy protects against development of SIVsmmPBj-induced acute disease. **J. Virol.** 73:8630-8639, 1999. PMCID: PMC112883

55. **Norton, R.A.**, Caserta, M.T., Hall, C.B., Schnabel, K., **Hocknell, P.** and **Dewhurst, S.** Detection of human herpesvirus-6 (HHV-6) by reverse transcription-PCR (RT-PCR). **J. Clin. Microbiol.** 37:3672-3675, 1999. PMCID: PMC85721

56. **Maggirwar, S.B., Ramirez, S.**, Tong, N., Gelbard, H.A. and **Dewhurst, S**. Functional interplay between NF-κB and c-jun integrated by coactivator p300 determines the survival of nerve growth factor-dependent PC12 cells. **J. Neurochem.** 74:527-540, 2000.

57. Tong, N., Zhang, Q., James, H.J., Kinnear, S.A., Perry, S.W., Guo, H., Brooks, A., **Bal, H., Fine, S.**, Gendelman, H.E., Epstein, L.G., Dairaghi, D., **Dewhurst, S.**, Sharer, L.R., Schall, T.J. and Gelbard, H.A. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the CNS. **J. Immunol.** 164:1333-1339, 2000.

58. **Skrincosky, D., Hocknell, P., Whetter, L.,** Secchiero, P., Chandran, B., and **Dewhurst S.** Identification and analysis of a novel heparin-binding glycoprotein encoded by human herpesvirus 7. **J. Virol.** 74:4530-4540, 2000.

59. **Bal, H.,** Chroboczek, J., Schoehn, G., Ruigrok, R.W.H., and **Dewhurst, S**. Adenovirus type 7 penton: purification of soluble pentamers from E. coli and development of an integrin-dependent gene delivery system. **Eur. J. Biochem.** 267:6074-6081, 2000.

60. Tong, N., **Sanchez, J., Maggirwar, S.B., Ramirez, S.,** Guo, H., **Dewhurst, S**., and Gelbard, H.A. Activation of glycogen synthase kinase 3 beta (GSK-3β) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. **Eur. J. Neurosci.** 13:1913-1922, 2001.

61. **Ramirez, S.H., Sanchez, J., Dimitri, C.,** Gelbard, H.A., **Dewhurst, S.**, and **Maggirwar, S.B.** Neurotrophins prevent neuronal apoptosis via a nuclear factor-κB (NF-κB)-dependent mechanism. **J. Neurochem.** 78:874-889, 2001.

62. **Skrincosky, D.,** Willis, R.A., **Hocknell, P.,** Frelinger, J.G., Mirandola, P., **Wang, X.,** and **Dewhurst, S.** Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies. **Arch. Virol.** 146:1705-1722, 2001. PMCID: PMC111973

63. **Hocknell, P.K., Wiley, R.D., Wang, X.**, Evans, T.G., Bowers, W.J., Hanke, T., Federoff, H.J., and **Dewhurst, S**. Expression of human immunodeficiency virus-1 gp120 from herpes simplex virus-1 derived amplicons results in potent, specific and durable cellular and humoral immune responses. **J. Virol.** 76:5565-5580, 2002. PMCID: PMC137011

64. **Richards J., Miller, M., Abend, J.,** Koide, A., Koide, S., and **Dewhurst, S**. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human αvβ3 integrin. **J. Mol. Biol**. 326:1475-1488, 2003.

65. **Richards J., Abend, J., Miller, M., Chakraborty-Sett, S., Dewhurst, S., and Whetter, L.** A peptide containing a novel FPGN CD40-binding sequence enhances adenoviral infection of murine and human dendritic cells. **Eur. J. Biochem**. 270: 2287-2294, 2003.

66. **Wang, X., Wiley, R.D.,** Evans, T.G., Bowers, W.J., Federoff, H.J., and **Dewhurst, S**. Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. **Vaccine** 21:2288-2297, 2003.

67. **Wang, X.,** Messerle, M., **Sapinoro, R., Santos, K., Hocknell, P.K**., Jin, X., and **Dewhurst, S**. Murine cytomegalovirus abortively infects human dendritic cells, leading to expression of virally-vectored genes and enhanced immunostimulatory activity. **J. Virol.** 77:7182-7192, 2003. PMCID: PMC164805

68. **Bradel-Tretheway, B., Zhen, Z.,** and **Dewhurst S**. Effects of codon-optimization on protein expression by the human herpesvirus (HHV)-6 and –7 U51 open reading frame. **J. Virol. Meth**. 111:145-156, 2003.

69. Diamond, T.L., Souroullas, G., Weiss, K.K., Lee, K.Y., Bambara, R.A., **Dewhurst, S**., and Kim, B. Mechanistic understanding of an altered fidelity simian immunodeficiency virus (SIV) reverse transcriptase (RT) mutation, V148I, identified in a pig-tailed macaque. **J. Biol. Chem**. 278:29913-24, 2003.
70. Dou, H., Birusingh, K., Faraci, J., Gorantla, S., Poluektova, L.Y., Maggirwar, S., **Dewhurst, S**., Gelbard, H.A., and Gendelman, H.E. Neuroprotective activities of sodium valproate in a murine model of HIV-1 encephalitis. **J. Neurosci.** 23:9162-9170, 2003.
71. **Zhen, Z., Bradel-Tretheway, B.G., Dewhurst, S**., and Bidlack, J.M. Transient overexpression of κ and μ opioid receptors using recombinant adenovirus vectors. **J. Neurosci. Methods** 136:133-139, 2004.
72. Latchney, L.R., Fallon M.A., Culp, D.J., Gelbard, H.A., and **Dewhurst, S.** Immunohistochemical Assessment of Fractalkine, Inflammatory Cells and Human Herpes Virus 7 in Human Salivary Glands. **Histochem. Cytochem**. 52:671-681, 2004.
73. **Ramirez, S.H., Fan, S., Maguire, C.A.,** Perry, S., Hardieck, K., Ramkumar, V., Gelbard, H.A., **Dewhurst, S**., Maggirwar, S. Adenosine A2A receptor protects sympathetic neurons against neurotrophin withdrawal. **J. Neurosci. Res**. 77:258-269, 2004.
74. Caserta, M.T., Schnabel, K., Carnahan, J.J., Gilbert, L., Lathan, G., **Dewhurst, S**., Lofthus, G.K., Boettrich, C., McDermott, M.P., and Hall, C.B. Human herpesvirus 6 (HHV6) DNA persistence and reactivation in normal children. **J. Pediatr.** 145:478-84, 2004.
75. Hall, C.B., Caserta, M.T., Schnabel, K.C., Boettrich, C., McDermott, M.P., Lofthus, G.K., Carnahan, J.A., and **Dewhurst, S**. Congenital infections with human herpesviruses 6 and 7. **J. Pediatr.** 145:472-477, 2004.
76. Diamond, T.L., Roshal, M., Jamburuthugoda, V., Reynolds, H.M., Merriam, A.R., Lee, K.Y., Balakrishnan, M., Bambara, R.A., Planelles, V., **Dewhurst, S**., and Kim, B. Macrophage tropism of HIV-1 depends upon efficient cellular dNTP utilization by reverse transcriptase. **J. Biol. Chem**. 271:51545-53, 2004. PMCID: PMC1351161
77. **Fan, S., Ramirez, S.H., Garcia, T., Dewhurst, S**. Overexression of Dishevelled induces morphological and cytoskeletal rearrangement in neuronally differentiated N2A neuroblastoma cells, via a GSK-3beta independent but DIX-domain dependent pathway. **Brain Res**. 132:38-50, 2004.
78. **Renda, M**., **Bradel-Tretheway, B.,** Bambara, R., **Dewhurst, S**., and Planelles, V. Lentiviral delivery of tRNAlys3 A58U inhibits HIV-1 replication in CEM cells. **AIDS Res. Hum. Retrovir**. 20:1324-34, 2004.
79. Gorantla S., **Santos, K.,** Meyer, V., **Dewhurst S**., Bowers, W.J.,. Federoff, H.J., Gendelman, H.E., and Poluektova, L. Human dendritic cells transduced with Herpes Simplex Virus (HSV) amplicons encoding HIV-1gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. **J. Virol**. 79:2124-32, 2005. PMCID: PMC546587
80. **Fan, S., Maguire, C.A., Ramirez, S.H., Bradel-Tretheway, B., Sapinoro, R.,** Sui, Z., **Chakraborty-Sett, S**., **Dewhurst, S.** Valproic acid enhances gene expression from viral gene transfer vectors. **J. Virol. Meth.** 125:23-33, 2005.
81. Jin, N., Kovacs, A., Sui, Z., **Dewhurst, S**., Maggirwar, S. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. **Neuropharmacology** 48:576-583, 2005.
82. Perry, S.W., Norman, J.P., Litzburg, A., **Dewhurst, S**., Gelbard, H.A. HIV-1 Tat induces mitochondrial hyperpolarization and synaptic stress leading to apoptosis. **J. Immunol.** 174:4333-4444, 2005.

83. **Zhen, Z.*, Bradel-Tretheway, B.*,** Sumagin, S., Bidlack, J.M., **Dewhurst, S**. The human herpesvirus (HHV)-6 GPCR homolog U51 positively regulates virus replication and enhances cell-cell fusion *in vitro*. **J. Virol.** 79:11914-24, 2005. **: Co-First Authors. Selected by the journal editors as "an article of significant interest"* PMCID: PMC1212626

84. Dou, H., Ellison, B., Bradley, J., Kasiyanov, A., Poluektova, L., Xiong, H., Maggirwar, S., **Dewhurst, S.,** Gelbard, H.A., and Gendelman, H.E. Neuroprotective mechanisms of lithium in murine HIV-1 encephalitis. **J. Neurosci.** 25: 8375-85, 2005.

85. **Zanghi, C.N. *, Lankes, H.A. *, Bradel-Tretheway, B., Wegman, J., and Dewhurst, S**. A simple method for displaying recalcitrant proteins on the surface of bacteriophage lambda. **Nucleic Acids Res.** 33:e160, 2005. **: Co-First Authors.* PMCID: PMC1258178

86. **Maguire, C.A., Sapinoro, R., Girgis, N., Rodriguez-Colon, S.M., Ramirez, S.H., Williams, J., and Dewhurst, S**. Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and $\alpha_v\beta_3$ integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens. **Vaccine** 24(5):671-682, 2006. PMCID: PMC1420683

87. Zeng, L., Planelles, V., Sui, Z., Gartner, S., Maggirwar, S.B., **Dewhurst, S.**, Ye, L., Nerurkar, V.R., Yanagihara, R., Lu, Y. HIV-1 based defective lentiviral vectors efficiently transduce human monocyte-derived macrophages and suppress replication of wild-type HIV-1. **J. Gene Med**. 8(1):18-28, 2006. PMCID: PMC2825118

88. Hall, C.B., Caserta, M.T., Schnabel, K.C., McDermott, M.P., Lofthus, G.K.., Carnahan, J.A., Gilbert, L.M., and **Dewhurst, S**. Characteristics and acquisition of Human Herpesvirus 7 (HHV7) infections in relation to infection with Human Herpesvirus 6 (HHV6)**. J. Infect. Dis**. 193:1063-1069, 2006.

89. Sui, Z., Sniderhan, L., **Fan, S**., Kazmierczak, K., Reisinger, E., Kovács, A.D., Potash, M.J., **Dewhurst, S.,** Gelbard, H.A., and Maggirwar, S.B. Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase (GSK)-3β activity to antagonize nuclear factor (NF)-κB survival pathway in neurons. **Eur. J. Neurol**. 23:2623-34, 2006.

90. Sui, Z.*, **Fan, S.*,** Sniderhan, L., Gelbard, H.A., **Dewhurst, S#** and Maggirwar, S. Inhibition of mixed lineage kinase (MLK)-3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. **J. Immunol.** 177:702-11, 2006. **: Co-First Authors; #: Corresponding Author.*

91. **Santos, K., Duke, C., Rodriguez-Colon, S.M., Dakwar, A., Fan, S.,** Federoff, H.J., Keefer, M.C., Bowers, W.J., **Dewhurst, S**. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. **Vaccine** 25:1634-1646, 2007. PMCID: PMC1851942

92. Chugh, P., **Fan, S**., Planelles, V., Maggirwar, S.B., **Dewhurst, S**., and Kim, B. Infection of Human Immunodeficiency Virus and Intracellular Viral Tat Protein Exert a Pro-Survival Effect in a Human Microglial Cell Line. **J. Mol. Biol.** 366:67-81, 2007.

93. **Lankes, H.A. *, Zanghi, C.N. *, Santos, K., Capella, C., Duke, C.M.P., and Dewhurst, S**. *In vivo* gene delivery and expression by bacteriophage lambda vectors. **J. Appl. Microbiol.** 102:1337-1349, 2007. **: Co-First Authors.* PMCID: PMC2063594

94. **Santos, K.*,** Simon, D.A.L.*, **Conway, E.,** Bowers, W.J., Mitra, S., Foster, T.H., Lugade, A., Lord, E., Federoff, H.J., **Dewhurst, S**., and Frelinger, J.G. Spatial and temporal expression of HSV-1 amplicon encoded genes: implications for their use as immunization vectors. **Hum. Gene Ther.** 18(2):1-13, 2007. *: Co-First Authors.

95. Sui, Z., Sniderhan, L., Schifitto, G., Phipps, R.P., Gelbard, H.A., **Dewhurst, S**., Maggirwar, S.B. Functional synergy between CD40L and HIV-1 Tat contributes to inflammation: implications in HIV-1 dementia. **J. Immunol**. 178:3226-3236, 2007.

96. Gorantla, S., Sneller, H., Walters, L., Sharp, J.G., Pirruccello, S.J., West, J., Wood, C., **Dewhurst, S**., Gendelman, H.E., Poluektova, L. A new paradigm for studies of HIV-1 pathobiology in humanized Balb/c-Rag2-/-γc-/- mice. **J. Virol**. 81:2700-2712, 2007. PMCID: PMC1865995

97. **Zanghi, C.N., Sapinoro, R., Bradel-Tretheway, B., Dewhurst, S**. A tractable method for simultaneous modifications to the head and tail of bacteriophage lambda and its application to enhancing phage mediated gene delivery. **Nuc. Acids Res**. 37: e59, 2007. PMCID: PMC1885665

98. Malboeuf, C.M., Simon, D.A.L., Lee, Y.E., **Lankes, H., Dewhurst, S.** Frelinger, J.G., Rose, R.C. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen-presenting cells *in vivo*. **Vaccine** 25:3270-6, 2007.

99. **Santos, K.*, Sanfilippo, C.M.*,** Narrow, W.C., Casey, A.E., Rodrigez-Colon, S.M. McDermott, M.P., Federoff, H.J., Bowers, W.J., **Dewhurst, S**. Infectivity of Herpes Simplex Virus Type-1 (HSV-1) amplicon vectors in dendritic cells is determined by the helper virus strain used for packaging. **J. Virol. Methods** 145:37-46, 2007. PMCID: PMC2080840. **: Co-First Authors.*

100. **Duke, C., Maguire, C.A.,** Keefer, M.C., Federoff, H.J., Bowers, W.J., **Dewhurst, S**. HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. **Vaccine** 25:7410-21, 2007. PMCID: PMC2092414. *Selected by Faculty of 1000 (F1000): Recommended paper (http://www.f1000.medicine.com).*

101. **Sapinoro, R., Maguire, C.A., Burgess, A., Dewhurst, S**. Enhanced transduction of dendritic cells by FcγRI-targeted adenovirus vectors. **J. Gene Med**. 9:1033-45, 2007.

102. Taylor, S.R.J., Gonzalez, M., **Dewhurst, S**., Chimini, G., Higgins, C.F., Melvin, J.E., Elliott, J.I. Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death. **J. Immunol.** 180:300-8, 2008.

103. Chugh, P., **Bradel-Tretheway, B**., Monteiro-Filho, C.M.R., Planelles, V., Maggirwar, S.B., **Dewhurst S**., Kim, B. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. **Retrovirology** 5:11, 2008. PMCID: PMC2265748

104. **Sapinoro, R**., **Volcy, K.,** Rodrigo, W.W.S.I., Schlesinger, J.J., **Dewhurst S**. Fc receptor mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells. **Virology** 373:274-286, 2008. PMCID: PMC2405766

105. **Bradel-Tretheway, B**., Kelley, Z., **Chakraborty-Sett, S**., Takimoto, T., Kim, B., **Dewhurst, S**. The human H5N1 influenza A virus polymerase complex is active in vitro over a broad range of temperatures, in contrast to the WSN complex, and this property can be attributed to the PB2 subunit. **J. Gen. Virol.** 89:2923-32, 2008. *Selected for inclusion in JGV Direct, a web-based service for rapid publication of JGV papers that are considered by the Editors to be of special importance.* PMCID: PMC3067610

106. Norman, J.P., Perry S.W., Reynolds, H.M., Kiebala, M., Bentley, K.M., Trejo, M., Volsky, D.J., Maggirwar, S.B., **Dewhurst, S**., Masliah, E., Gelbard, H.A. HIV-1 Tat Activates Neuronal Ryanodine Receptors with Rapid Induction of the Unfolded Protein Response and Mitochondrial Hyperpolarization. **PLoS ONE** 3(11):e3731. Epub Nov 14., 2008. PMCID: PMC2579580

107. **Volcy, K., Dewhurst, S.** Proteasome Inhibitors Enhance Bacteriophage Lambda (λ) Mediated Gene Transfer in Mammalian Cells. **Virology** 384:277–87, 2009. PMCID: PMC2654414

108. Schifitto, G., Zhong, J., Gill, D., Peterson, D.R., Gaugh, M.D., Zhu, T., Tivarus, M., Cruttenden, K., Maggirwar, S.B., Gendelman, H.E., **Dewhurst, S**., Gelbard, H.A. Lithium

Therapy for HIV-1 Associated Neurocognitive Impairment. **J. Neurovirol.** 22:1-11, 2009. PMCID: PMC2747099.

109. Bimber, B.N., Chugh, P., Giorgi, E.E., Kim, B., Almudevar, A.L., **Dewhurst, S.**, O'Connor, D.H., Lee, H.Y. Nef gene evolution from a single transmitted strain in acute SIV infection. **Retrovirology**, 6:57, 2009. PMCID: PMC2701916
110. Kennedy, E., Hergott, C., **Dewhurst, S.,** Kim, B. The Mechanistic Architecture of the Thermostable *Pyrococcus Furiosus* Family B DNA Polymerase Motif A and its Interaction with dNTP Substrate. **Biochemistry,** 48(47):11161-8, 2009. PMCID: PMC3097049
111. Eggert, D., Dash, P.K., Gorantla, S., Dou,H., Schifitto, G., Maggirwar, S.B., **Dewhurst, S**., Poluektova, L., Gelbard, H.A., Gendelman, H.E. Neuroprotective Activities of CEP-1347 in Models of HIV-1 Encephalitis. **J. Immunol**., 184(2):746-56, 2010. PMCID: PMC2805820
112. Desmet, E., Hollenbaugh, J.A., Sime, P.J., Topham, D.J., Sant, A.J., Takimoto, T., **Dewhurst, S**., and Maggiwar, S.B. Mixed Lineage Kinase 3 deficiency delays viral clearance in the lung and is associated with diminished influenza-induced cytopathic effect in infected cells. **Virology** 400(2):224-32, 2010. PMCID: PMC2844475
113. Love, T.M.T., Thurston, S.W., Keefer, M.C., **Dewhurst, S.**, Lee, H.Y. Quantification of Simian Immunodeficiency Virus Escape Dynamics from CD8+ T lymphocytes in Vaccinated and Unvaccinated Macaques using Ultradeep Pyrosequencing. Mathematical Modeling of Ultradeep Sequencing Data Reveals That Acute CD8+ T-Lymphocyte Responses Exert Strong Selective Pressure in Simian Immunodeficiency Virus-Infected Macaques, but Still Fail to Clear Founder Epitope Sequences. **J. Virol.** 84:5802-5814, 2010. PMCID: PMC2876615
114. Aggarwal, S., **Bradel-Tretheway, B.,** Takimoto, T., **Dewhurst, S**., Kim, B. Biochemical Characterization of Enzyme Fidelity of Influenza A Virus RNA Polymerase Complex. **PLOS One** 5(4): e10372, 2010. PMCID: PMC2861597
115. Gorantla, S., Makarov, E., Finke-Dwyer, J., Gebhart, C.L., **Domm, W.**, **Dewhurst, S.,** Gendelman, H.E., Poluektova, L.Y., Depletion of CD8+ cells accelerates HIV-1 replication in humanized mice. **J. Immunol.** 184 7082-7091, 2010. PMCID: PMC3008566
116. **Olsen, J.T, Brown, C.,** Rubinshtein, M., Capule, C.C., Srivastava, R.K., Pool, S.H., Feng, C., Nilsson, B.C., Yang, J., **Dewhurst, S**. Amyloid binding small molecules efficiently block SEVI and semen mediated enhancement of HIV-1 infection. **J. Biol. Chem.,** 285: 35488-35496, 2010. PMCID: PMC2975173
117. **Polesskaya, O.,** Cunningham, L.L., Francis, S.P., Luebke, A.E., Zhu, X., **Collins, D.,** Vasilyeva, O.N., **Sahler, J.,** Desmet, E.A., Gelbard, H.A., Maggirwar, S.B., Walton, J.P., Frisina, R.D., **Dewhurst, S.** Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure. **Hearing Res**. 270:21-7, 2010. PMCID: PMC2997883
118. **Polesskaya, O., Silva, J., Sanfilippo, C., Desrosiers, T.,** Sun, A., **Shen, J.,** Feng, C., **Polesskiy, A.,** Deane, R., Zlokovic, B., Kasischke, K., **Dewhurst, S.** Methamphetamine causes sustained depression in cerebral blood flow. **Brain Res.** 1373:91-100, 2011. PMCID: PMC3026925
119. **Mattiacio, J., Domm, W., Walter, S., Brewer, M.,** Friedman, A.E., **Dewhurst, S.** Ordered, dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env. **Vaccine** 29:2637-2647, 2011. PMCID: PMC3062207
120. **Easterhoff, D.**[*]**,** DiMaio, J.T.M.[*], Doran, T., **Dewhurst, S**.[#], Nilsson, B.L.[#] Enhancement of HIV-1 infectivity by simple, self-assembling modular peptides. **Biophys. J**. 100:1325–

1334, 2011. *: Contributed equally. #: Co-Communicating authors. PMCID: PMC3043227

121. Cao, S., Wu, C., Yang, Y., Sniderhan, L.F., Maggirwar, S., **Dewhurst, S**., Lu, Y. Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS. **J. Neuroinflamm**. 8:48, 2011. PMCID: PMC3118348
122. Bussey, K.A., Desmet, E.A., **Mattiacio, J.L**., Hamilton, Bradel-Tretheway, B., Bussey, H.E., Kim, B., **Dewhurst, S.,** Takimoto, T. PA residues in the 2009 H1N1 pandemic influenza virus enhance avian virus polymerase activity in mammalian cells. **J. Virol**. 85:7020-8, 2011. PMCID: PMC3126589.
123. Bradel-Tretheway, B.*, **Mattiacio, J**.*, Krasnoselsky, A., **Stevenson, C**., Purdy, D., **Dewhurst S#**, Katze, M.G.# Comprehensive Proteomic Analysis of Influenza Virus Polymerase Complex Reveals a Novel Association with Mitochondrial Proteins and RNA Polymerase Accessory Factors. **J. Virol**., 85:8569-81, 2011. *: Contributed equally; #: Contributed equally; Co-corresponding authors. PMCID: PMC3165779
124. Hazard, M., Steele, S., Wang, D., Pearson, T., Scheideler, M., **Dewhurst, S.** CTSA-IP: A solution to identifying and aggregating intellectual property across the NIH Clinical-Translational Science Award (CTSA) consortium of biomedical research institutes. **Clin. Translat. Sci.,** 4:328-331, 2011. PMCID: PMC3670705
125. **Domm, W., Brooks, L.,** Chung, H.-L., Feng, C., Bowers, W.J., Watson, G.E., McGrath, J.L., **Dewhurst, S**. Robust Antigen-Specific Humoral Immune Responses to Sublingually Delivered Adenoviral Vectors Encoding HIV-1 Env: Association with Mucoadhesion and Efficient Penetration of the Sublingual Barrier. **Vaccine**, 29:7080-9, 2011. PMCID: PMC3167942
126. Lu, S.-M., Tremblay, M.E., King, I.L., Qi, J., Reynolds, H.M., Marker, D.F., Varrone, J.P., Kasischke, K.A., Majewska, A.K., **Dewhurst, S**., Gelbard, H.A. HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. **PLoS ONE**, 6(9):e23915, 2011. PMCID: PMC3166280
127. Aggarwal, S., **Dewhurst, S**., Takimoto, T., Kim, B. Biochemical impact of the host adaptation-associated PB2 E627K mutation on the temperature-dependent RNA synthesis kinetics of influenza A virus polymerase complex. **J Biol Chem.** 286:34504-13, 2011. PMCID: PMC3186381
128. **Fong, V., Osterbur, M., Capella, C., Kim, Y.-L.,** Hine, C., Gorbunova, V., Seluanov, A., **Dewhurst, S**. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells. **PLoS ONE** 6(12): e28714, 2011. PMCID: PMC3235156
129. Arany, S., **Xu, Q**., Hernady, E., Benoit, D.S., **Dewhurst, S**., Ovitt, C.E. Pro-apoptotic gene knockdown mediated by nanocomplexed siRNA reduces radiation damage in primary salivary gland cultures. **J. Cell. Biochem.** 113:1955-65, 2012. PMCID: PMC3360791
130. Capule, C.C., **Brown, C., Olsen, J.S.**, **Dewhurst, S**.#, Yang, J.#. Oligovalent Amyloid-Binding Agents Reduce SEVI-Mediated Enhancement of HIV-1 Infection. **J Am Chem Soc.** 134:905-8. 2012.#: Co-Communicating authors. PMCID: PMC3262105
131. **Olsen, J.S**., DiMiao, J.T.M., Doran, T.M., **Brown, C**., Nilsson, B.L., **Dewhurst, S**. Seminal Plasma Accelerates SEVI Fibril Formation by the PAP[248-286] Peptide**. J. Biol. Chem**. 287:11842-9, 2012. PMCID: PMC3320932
132. **Polesskaya, O.,** Sun, A., Salahura, G., **Silva, J.N., Dewhurst, S.,** Kasischke, K. Detection of microregional hypoxia in mouse cerebral cortex by two-photon imaging of endogenous NADH fluorescence. **J. Vis. Exp. (JoVE),** Feb 21;(60). pii: 3466. doi: 10.3791/3466, 2012. PMCID: PMC3376929

133. Kobie, J.J., Alcena, D.C., Zheng, B., Bryk, P., **Mattiacio, J.L., Brewer, M.**, Labranche, C., Young, F.M., **Dewhurst, S.**, Montefiori, D.C., Rosenberg, A.F., Feng, C., Jin, X., Keefer, M.C., Sanz, I. 9G4 Autoreactivity Is Increased in HIV-Infected Patients and Correlates with HIV Broadly Neutralizing Serum Activity. **PLoS One** 7(4):e35356, 2012. PMCID: PMC3329433

134. **Capella, C., Beltejar, M., Brown, C., Fong, V.,** Daddacha, W., Kim, B., **Dewhurst, S**. Identification of adenovirus type 5 DNA polymerase mutants that modify viral host range and replication efficiency. **J. Virol.** 86:10484-93, 2012. PMCID: PMC3457291

135. **Silva, J., Polesskaya, O.,** Knight, W., **Zheng, J.T., Granger, M., Lopez, T., Ontiveros, F.**, Feng, C., Yan, C., Kasischke, K.A., **Dewhurst, S**. Transient Hypercapnia Reveals an Underlying Cerebrovascular Pathology in a Murine Model for HIV-1 Associated Neuroinflammation: Role of NO-cGMP Signaling and Normalization by Inhibition of Cyclic Nucleotide Phosphodiesterase-5. **J. Neuroinflamm**. 9:253, 2012. doi: 10.1186/1742-2094-9-253. PMCID: PMC3526511

136. Sullivan, M., **Brooks, L.R.,** Weidenborner, P.J., **Domm, W., Mattiacio, J.L., Xu, Q.,** Tiberio, M., Wentworth, T.J., Kobie, J.J., Bryk, P., Zheng, B., Murphy, M., Sanz, I., **Dewhurst, S**. Anti-Idiotypic Monobodies Derived from a Fibronectin Scaffold. **Biochemistry** 12:1802-13, 2013. PMCID: PMC4090420

137. **Easterhoff, D.*, Ontiveros, F.*, Brooks, L., Kim, Y., Ross, B., Silva, J., Olsen, J.S.**, Feng, C., Hardy, D.J., Dunman, P.M., **Dewhurst, S**. The semen enhancer of viral infection (SEVI) binds bacteria, enhances bacterial phagocytosis by macrophages, and can protect against vaginal infection by a sexually transmitted bacterial pathogen. **Antimicrob. Ag. Chemother.** 57:2443-50, 2013. *: Co-first authors. PMCID: PMC3716189

138. Lu, N., **Silva, J.,** Gu, Y., Gerber, S., Wu, H., Gelbard, H., **Dewhurst, S.,** Miao, H. Directional Histogram Ratio at Random Probes: A Local Thresholding Criterion for Capillary Images. **Pattern Recognition** 46:1933-1948, 2013. PMCID: PMC3601758

139. Arany S., Benoit, D.S.W., **Dewhurst, S.,** Ovitt, C.E. Nanoparticle mediated gene silencing confers radioprotection to salivary glands in vivo. **Mol. Ther**. 21(6):1182-94, 2013. PMCID: PMC3677305.

140. Marker, D., Tremblay, M.-E., Puccini, J., Barbieri, J., Marker, M.G., Loweth, C., Muly, E., Lu, S.-M., Goodfellow, V., **Dewhurst, S**., Gelbard, H.A. The new small molecule mixed lineage kinase 3 inhibitor, URMC-099, is neuroprotective and anti-inflammatory in models of HIV associated neurocognitive disorders. **J. Neurosci**. 33(24):9998-1001, 2013. PMCID: PMC3682381.

141. **Easterhoff, D**., DiMiao, J., Liyanage, W., **Lo, C-W., Bae, W.,** Doran, T., Smrcka, A., Nilsson, B., **Dewhurst, S**. Fluorescence detection of cationic amyloid fibrils in human semen. **Bioorgan. Med. Chem. Lett.** 23:5199-202, 2013. PMCID: PMC3895278.

142. Ma, Q., Gelbard, H.A., Maggirwar, S.B., **Dewhurst, S.**, Gendelman, H.E., Peterson, D.R., DiFrancesco, R., Hochreiter, J.S., Morse, G.D., Schifitto, G. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. **J Neurovirol.** 19:254-60, 2013. PMCID: PMC3760277.

143. Mapstone, M., Hilton, T.N., Yang, H., Guido, J., Luque, A.E., Hall, W.J., **Dewhurst, S**., Shah, K. Poor Aerobic Fitness May Contribute to Cognitive Decline in HIV-infected Older Adults. **Aging & Disease** 4:311-9, 2013. PMCID: PMC3843648

144. Goodfellow, V., Loweth, C., Ravula, S., Wiemann, T., Nguyen, T., Xu, Y., Todd, D., Sheppard, D., Pollack, S., **Polesskaya, O**., Marker, D., **Dewhurst, S**., Gelbard, H. Discovery, Synthesis and Characterization of an Orally Bioavailable, Brain Penetrant

Inhibitor of Mixed Lineage Kinase 3. **J. Med. Chem.** 56:8032-48, 2013. PMCID: PMC4032177

145. Alcéna, D.C., Kobie, J.J., Kaminski, D.A., Rosenberg, A.F., **Mattiacio, J.L., Brewer, M., Dewhurst, S.,** Dykes, C., Jin, X., Keefer, M.C., Sanz, I. 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles. **PLoS ONE** 8(12):e85098, 2013. PMCID: PMC3873436
146. **Domm, W., Brewer, M.,** Baker, S.F., Feng, C., Martínez-Sobrido, L., Treanor, J., **Dewhurst, S**. Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies. **J. Virol. Methods**, 197:47-50, 2014. PMCID: PMC4037851
147. **Polesskaya, O., Wong, C., Lebron, L., Chamberlain, J.M.,** Gelbard, H.A., Goodfellow, V., Kim, M., Daiss, J.L., **Dewhurst, S.** MLK3 regulates fMLP-stimulated neutrophil motility. **Molec. Immunol.** 58:214-22, 2014. PMCID: PMC3946811
148. Lewis, C.A., **Dewhurst, S**., McMahon, J.M., Bunce, C.A., Keefer, M.C., Alio, A.P. Theoretical model of critical issues in informed consent in HIV vaccine trials. **AIDS Care.** 28:1-9, 2014. PMCID: PMC4122591
149. **Silva, J.N., Polesskaya, O.,** Wei, H.S., Rasheed, I.Y., **Chamberlain, J.M., Nishimura, C.,** Feng, C., **Dewhurst, S**. Chronic Central Nervous System Expression of HIV-1 Tat Leads to Accelerated Rarefaction of Neocortical Capillaries and Loss of Red Blood Cell Velocity Heterogeneity. **Microcirculation** 21:664-76, 2014. PMCID: PMC4194156
150. Nogales, A., Baker, S.F., Ortiz-Riaño, E., **Dewhurst, S.**, Topham, D.J., Martínez-Sobrido, L. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. **J Virol.** 88:10525-40, 2014. PMCID: PMC4178899
151. **Rhoo, K.H., Granger, M., Sur, J.,** Feng, C., Gelbard, H.A., **Dewhurst, S**., **Polesskaya, O.** Pharmacologic Inhibition of MLK3 Kinase Activity Blocks the In Vitro Migratory Capacity of Breast Cancer Cells but Has No Effect on Breast Cancer Brain Metastasis in a Mouse Xenograft Model. **PLoS One** 9(9):e108487, 2014. PMCID: PMC4180451.
152. Ying, B., Tollefson, A.E., Spencer, J.F., Balakrishnan, L., **Dewhurst, S., Capella, C.**, Buller, R.M., Toth, K., Wold, W.S. Ganciclovir Inhibits Human Adenovirus Replication and Pathogenicity in Permissive Immunosuppressed Syrian Hamsters. **Antimicrob Agents Chemother.** 58:7171-81, 2014. PMCID: PMC4249575.
153. **Cox, A**.*, Baker, S.F.*, Nogales, A., Martínez-Sobrido, L.[#], **Dewhurst, S**[#]. Development of a mouse-adapted, live-attenuated influenza virus that permits *in vivo* analysis of enhancements to the safety of LAIV. **J. Virol.** 89:3421-6, 2015. PMCID: PMC4337518 *: Contributed equally; [#]Co-corresponding authors.
154. Sheik, D.A., **Brooks, L., Frantzen, K., Dewhurst, S.**, Yang, J. Inhibition of the enhancement of infection of human immunodeficiency virus by semen-derived enhancer of virus infection using amyloid-targeting polymeric nanoparticles. **ACS Nano.** 9:1829-36, 2015. PMCID: PMC4426188 *: Contributed equally
155. Puccini, J.M., Marker, D.F., Fitzgerald, T., Barbieri, J., Kim, C.S., Miller-Rhodes, P., Lu, S.M., **Dewhurst, S.**, Gelbard, H.A. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. **J Neurosci.** 35:5271-83, 2015. PMCID: PMC4381000
156. Blanchard, C.*, **Brooks, L.***, Beckley, A., Colquhoun, J., **Dewhurst, S.**, Dunman, P.M. Neomycin sulfate improves the antimicrobial activity of mupirocin-based antibacterial ointments. **Antimicrob Agents Chemother.** 60:862-72, 2015. *: Contributed equally. PMCID: PMC4750660

157. **Cox, A., Dewhurst, S**. A single mutation at PB1 residue 319 dramatically increases the safety of PR8 LAIV in a murine model without compromising vaccine efficacy. **J. Virol**. 90:2702-5, 2015. PMCID: PMC4810719

158. **Cox, A.***, Baker, S.F.*, Nogales, A., Martínez-Sobrido, L.#, **Dewhurst, S.**#. Development of a mouse-adapted, live-attenuated influenza virus that permits *in vivo* analysis of enhancements to the safety of LAIV. **J. Virol.** 89:3421-6, 2015. PMCID: PMC4337518. **Contributed equally; #Co-corresponding authors*.

159. **Nishimura, C., Polesskaya, O., Dewhurst, S., Silva, J.N.** Quantification of cerebral vascular architecture using two-photon microscopy in a mouse model of HIV-induced neuroinflammation. **J Vis Exp.** 2016 Jan 12;(107). doi: 10.3791/53582.

160. Blanchard, C., **Brooks, L.**, Ebsworth-Mojica, K., Didione, L., Wucher, B., **Dewhurst, S.**, Krysan, D., Dunman, P.M., Wozniak, R.A. Zinc pyrithione improves the antibacterial activity of silver sulfadiazine ointment. **mSphere** 1(5). pii: e00194-16. PMCID: PMC5023846

161. Sheik, D.A., Chamberlain, J.M., Brooks, L., Clark, M., Kim, Y.H., Leriche, G., Kubiak, C.P., **Dewhurst, S**., Yang, J. Hydrophobic nanoparticles reduce the β-sheet content of SEVI amyloid fibrils and inhibit SEVI-enhanced HIV infectivity. **Langmuir** 33:2596-2602, 2017. PMID: 28207276. *Free open access article.*

162. **Brewer, M.G.,** DiPiazza, A., **Acklin, J.,** Feng, C., Sant, A.J., **Dewhurst, S**. Nanoparticles decorated with viral antigens are more immunogenic at low surface density. **Vaccine** 35(5):774-781, 2017. PMCID: PMC5876043

163. Hilimire, T.A., **Chamberlain, J.M.,** Anokhina, V., Bennett, R.P., Swart, O., Myers, J.R., Ashton, J.M., Stewart, R.A., Featherston, A.L., **Gates, K.,** Helms, E.D., Smith, H.C., **Dewhurst, S**., Miller, B.L. HIV-1 frameshift RNA-targeted triazoles inhibit propagation of replication-competent and multi-drug-resistant HIV in human cells. **ACS Chem Biol.** 2017 Jun 16;12(6):1674-1682. PMCID: PMC5477779

164. Mathew, E., Zhu H., Connelly, S.M., Sullivan, M.A., **Brewer, M.G.**, Piepenbrink, M.S., Kobie, J.J., **Dewhurst, S.**, Dumont, M.E. Display of the HIV envelope protein at the yeast cell surface for immunogen development. **PLoS One.** 13(10):e0205756, 2018. PMCID: PMC6193675

165. **Smith, A., Rodriguez-Garcia, L., El Ghouayel, M.,** Martínez-Sobrido, L.**, Dewhurst, S.** 993. Combining Key Residues of the Russian and US Live-Attenuated Influenza Viruses for a More Attenuated Virus. **Open Forum Infect Dis.** 2018 Nov; 5(Suppl 1): S294–S295. Published online 2018 Nov 26. doi: 10.1093/ofid/ofy210.830. PMCID: PMC6253618. *This article is, in effect, an extended meeting abstract (with Figures)*.

166. **Chamberlain, J.M., Sortino, K.,** Sethna, P., Bae, A., Lanier, R., Bambara R.A., **Dewhurst, S.** Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus. **Antimicrob Agents Chemother.** 63(1). pii: e01925-18. doi: 10.1128/AAC.01925-18, 2019. PMC6325223.

167. Rodriguez, L., Blanco-Lobo, P., Reilly, E.C., Maehigashi, T., Nogales, A., **Smith, A.,** Topham, D.J., **Dewhurst, S.**, Kim, B., Martínez-Sobrido, L. Comparative Study of the Temperature Sensitive, Cold Adapted and Attenuated Mutations Present in the Master Donor Viruses of the Two Commercial Human Live Attenuated Influenza Vaccines. **Viruses** 11(10). pii: E928, 2019. PMC6832241

168. Ma, Q., Schifitto G., Venuto, C., Ocque, A., **Dewhurst, S**., Morse, G.D., Aalinkeel, R., Schwartz, S.A., Mahajan, S.D. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB). **J Neuroimmune Pharmacol.** 15(1):7-9, 2020. PMC7141951

169. **Smith, A.,** Rodriguez, L., **Ghouayel, M.E.,** Nogales, A., **Chamberlain, J.M., Sortino, K.,** Reilly, E., Feng, C., Topham, D.J., Martínez-Sobrido, L., **Dewhurst, S**. A live-attenuated influenza vaccine (LAIV) elicits enhanced heterologous protection when the internal genes of the vaccine are matched to the challenge virus. **J. Virol.** 94(4):e01065-19, 2020. PMC6997774

170. Piekna-Przybylska, D., Bambara, R.A., Maggirwar, S.B., **Dewhurst, S.** G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells. **Cell Cycle** Aug 17:1-16, 2020. doi: 10.1080/15384101.2020.1796268. PMC7513862

171. **Simpson, S.R**., Singh, M.V., **Dewhurst, S**., Schifitto, G., Maggirwar, S.B. Platelets function as an acute viral reservoir during HIV-1 infection by harboring virus and T-cell complex formation. **Blood Advances** 4(18):4512-4521, 2020. PMC7509884

172. **Cox, A., Schmierer, J., D'Angelo, J., Smith, A., Levenson, D.,** Treanor, J., Kim, B., **Dewhurst, S.** A Mutated PB1 Residue 319 Synergizes with the PB2 N265S Mutation of the Live Attenuated Influenza Vaccine to Convey Temperature Sensitivity. **Viruses** 12(11):1246, 2020. PMC7693792

173. Dunman, P., Chojnacki, M., Dobrotka, C., **Osborn, R.**, Johnson, W., Young, M., Meyer, B., Laskey, E., Wozniak, R., **Dewhurst, S**. Evaluating the Antimicrobial Properties of Commercial Hand Sanitizers. **mSphere**, 6(2):e00062-21. doi: 10.1128/mSphere.00062-21, 2021. PMC8546682

174. Sherby, M.R., Kalb, LG; Coller, R.J., DeMuri, G.P., Butteris, S., Foxe, J.J., Zand, M.S., Freedman, E.G., **Dewhurst, S.,** Newland, J.G., Gurnett, C.A. Supporting COVID-19 School Safety for Children With Disabilities and Medical Complexity. **Pediatrics** 149(12 Suppl 2):e2021054268H, 2022. PMC8926067

175. Raymonda, M.H., Ciesla, J.H., Monaghan, M., **Leach, J**., Asantewaa, G., Smorodintsev-Schiller, L.A., Lutz IV, M.M., Schafer, X.L., Takimoto, T., **Dewhurst S.,** Munger, J., Harris, I.S. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. **Virology** 566:60-68, 2022. PMC8626825. *A preprint of an earlier version of this article appeared on the BioRxiv preprint server in 2020 (https://doi.org/10.1101/2020.11.25.398859).*

176. Nogales, A., Steel, J., Liu, W.C., Lowen, A.C., Rodriguez, L., Chiem, K., Cox, A., García-Sastre, A., Albrecht, R.A., **Dewhurst, S**., Martínez-Sobrido, L. Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine. **Microbiol Spectr.** 2022 Jun 29;10(3):e0007822. doi: 10.1128/spectrum.00078-22. PMC9241597

177. **Simpson, S**., McMinn, C., Van Mondfrans, S.M., Hendry, J., Ronayne, S., **Dewhurst, S**., Feng, C., Bal, B.S., Bock, R.M., McEntire, B.J.. A Novel Antipathogenic Agent for Nonwoven Fabric. **Biomedical Materials & Devices** (2022). Online. https://doi.org/10.1007/s44174-022-00001-8. PMC9299416

178. Zhou, T., Gilliam, N.J., Li, S., Spaudau, S., **Osborn, R.M**., Anderson, C.S., Mariani, T.J., Thakar, J., **Dewhurst, S.**, Mathews, D.H., Huang, L., Sun, Y. Generation and functional analysis of defective viral genomes during SARS-CoV-2 infection. **bioRxiv.** 2022 Sep 23:2022.09.22.509123. doi: 10.1101/2022.09.22.509123. PMC9516852

179. **Osborn, R.M., Leach, J.**, Zanche, M., Ashton, J., Chu, C.Y., Thakar, J., **Dewhurst, S**., Rosenberger, S., Pavelka, M., Pryhuber, G.S., Mariani, T., Anderson, C.S. Preparation of Noninfectious scRNAseq Samples from SARS-CoV-2-Infected Epithelial Cells. **PLOS One.** 2023 Feb 24;18(2):e0281898. doi: 10.1371/journal.pone.0281898. PMCID: PMC9956660

180. Goldman, J.L., Kalu, I.C., Schuster, J.E., Erickson, T., Mast, D.K., Zimmerman, K., Benjamin, D.K., Kalb, L.G., Gurnett, C., Newland, J.G., Sherby, M., Godambe, M., Shinde, N., Watterson, T., Walsh, T., Foxe, J., Zand, M., **Dewhurst, S.,** Coller, R., DeMuri, G.P., Archuleta, S., Ko, L.K., Inkelas, M., Manuel, V., Lee, R., Oh, H., Murugan, V., Kramer, J., Okihiro, M., Gwynn, L., Pulgaron, E., McCulloh, R., Broadhurst, J., McDaniels-Davidson, C., Kiene, S., Oren, E., Wu, Y., Wetter, D.W., Stump, T., Brookhart, M.A., Fist, A., Haroz, E. Building School-Academic Partnerships to Implement COVID-19 Testing in Underserved Populations. **Pediatrics.** 2023 Jul 1;152(Suppl 1):e2022060352C. doi: 10.1542/peds.2022-060352C. PMID: 37394512

181. Schuster, J.E., Erickson, T.R., Goldman, J.L., Benjamin, D.K., Brookhart, M.A., **Dewhurst, S.**., Fist, A., Foxe, J., Godambe, M., Gwynn, L., Kiene, S.M., Keener Mast, D., McDaniels-Davidson, C., Newland, J.G., Oren, E., Selvarangan, R., Shinde, N., Walsh, T., Watterson, T.Z.M., Zimmerman, K.O, Kalu, I.C. Utilization and Impact of Symptomatic and Exposure SARS-CoV-2 Testing in K-12 Schools. **Pediatrics.** 2023 Jul 1;152(Suppl 1):e2022060352I. doi: 10.1542/peds.2022-060352I, PMID: 37394504

182. Zand, M.S., Spallina, S., Ross, A., Zandi, K., Pawlowski, A., Seplaki, C., Herington, J., Corbett, A., Kaukeinen, K., Freedman, E., Holden-Wiltse, J., Alcantara, L., Li, D., Cameron, A., Beaumont, N., Dozier, A., **Dewhurst, S.,** Foxe, J. Ventilation during COVID-19 in a school for students with intellectual and developmental disabilities (IDD). **medRxiv** 2023.09.08.23295268; doi: https://doi.org/10.1101/2023.09.08.23295268

183. Rahman, S.M., Buchholz, D.W., Imbiakha, B., Jager, M.C., **Leach, J., Osborn, R.M.**, Birmingham, A.O., **Dewhurst, S.**, Aguilar, H.C., Luebke, A.E. SARS-CoV-2 induces acute neurological signs while Calcitonin Gene-Related Peptide (CGRP) signaling blockade reduces interleukin 6 (IL-6) release and weight loss in mouse models. **bioRxiv.** 2023 Nov 8:2023.10.23.563669. https://doi:10.1101/2023.10.23.563669; PMCID: PMC10634772

184. Molina Vargas, A.M., Sinha, S., **Osborn, R.,** Arantes, P.R., Patel, A., **Dewhurst, S.,** Hardy, D.J., Cameron, A., Palermo, G., O'Connell, M.R. New design strategies for ultra-specific CRISPR-Cas13a-based RNA detection with single-nucleotide mismatch sensitivity. **Nucleic Acids Res.** 2024 Jan 25;52(2):921-939. doi: 10.1093/nar/gkad1132. PMCID: PMC10810210 (see also **bioRxiv** 2023.07.26.550755; doi: https://doi.org/10.1101/2023.07.26.550755)

185. I.A., Byun, H., Adeleke, R.A., **Leach, J**., Whittaker, G., **Dewhurst, S.**, Rudd, B.D., Aguilar, H.C., and August, A. Adaptive immune cells are necessary for SARS-CoV-2-induced pathology. **Sci Adv.** 2024 Jan 5;10(1):eadg5461. doi: 10.1126/sciadv.adg5461. PMCID: PMC10775995

Book Chapters and Review Articles

1. Volsky, D.J., Sakai, K., Stevenson, M., and **Dewhurst, S.** Retroviral etiology of the acquired immune deficiency syndrome (AIDS). **AIDS Res. 2**:S35-S48, 1986.

2. Volsky, D.J., **Dewhurst, S.,** Stevenson, M., Sakai, K., Evinger-Hodges, M.J., and Bresser, J. Infection of human glial cells *in vitro* by human immunodeficiency virus (HIV). In: "Retroviruses of human AIDS and related animal diseases", Ed.: Girard, M., de The, G., and Valette, L. Pasteur Vaccins, Paris, 1986.

3. Merino, F., Rodriguez, L., **Dewhurst, S.,** Sinangil, F., and Volsky, D.J. Prevalence of antibodies to human T-lymphotropic virus types I and III (LAV) in healthy Venezuelan populations. In: "Viruses and Human Cancer". Alan R. Liss Inc., New York, 1987.

4. Mullins, J.I., Hoover, E.A., Donahue, P.R., **Dewhurst, S.,** Quackenbush, S., Murphey-Corb, M., Martin, L., Fultz, P.N., Gallo, M.V., Reinhart, T., and Overbaugh, J. The FeLV and SIV AIDS pathogenesis models: search for and analysis of molecularly defined pathogens. In: "Proceedings of the 21st Congress of the International Association of Biological Standarization (AIBS)". 1989.

5. Overbaugh, J., **Dewhurst, S.,** and Mullins, J.I. Proviral DNA cloning. In: "Techniques in HIV research", Ed: Aldovini, A., and Walker, B. D. Stockton Press, New York. 1990.

6. Fultz, P.N., Anderson, D.C., McClure, H.M., **Dewhurst, S.,** and Mullins, J.I. SIV_{smm} infection of macaque and mangabey monkeys: correlation between *in vivo* and *in vitro* properties of different isolates. **Dev. Biol. Stand.** 72:253-8, 1990.

7. Mullins, J.I., Hoover, E.A., Donahue, P.R., **Dewhurst, S.,** Quackenbush, S.L., Murphey-Corb, M., Martin, L.N., Fultz, P.N., Gallo, M.V., and Reinhart, T.A. The FeLV and SIV AIDS pathogenesis models: search for and analysis of molecularly defined pathogens. **Dev. Biol. Stand.** 72:167-71, 1990.

8. Contag, C.H., **Dewhurst, S.,** Viglianti, G.A., and Mullins, J.I. Simian immunodeficiency virus (SIV) from old world monkeys. In: "The Human Retroviruses", Ed: Gallo, R.C., and Gilbert, J., Academic Press, Orlando, Fl. 1991.

9. **Dewhurst, S.** Newly discovered human herpesviruses (HHV-6, HHV-7). **Curr. Opin. Infect. Dis.** 7:238-245, 1994.

10. **Dewhurst, S**., Gelbard, H.A., and **Fine, S.M**. Neuropathogenesis of AIDS *(featured on front cover).* **Mol. Med. Today** 2:16-23 1996.

11. **Dewhurst, S**., Sander, D.M., and Sgro, J.-Y. Resources for HIV/AIDS on the internet. **Mol. Med. Today** 2:52-57, 1996.

12. **Dewhurst, S., and Whetter, L.** Pathogenesis and treatment of HIV-1 infection: recent developments. **Frontiers Biosci.** 2, d148-159, 1997. *Full text online at: http://www.bioscience.org/1997/v2/d/dewhurs1/htmls/list.htm.*
Note: This review article was selected as one of the "best articles in the category of reviews in basic science" for 1997 in Frontiers in Bioscience.

13. **Dewhurst, S., Skrincosky, D., and van Loon, N.** Human herpesvirus 6. **Expert Reviews in Molecular Medicine**, 1997. *Full-text online at:* http://www-ermm.cbcu.cam.ac.uk/sdr/txt001sdr.htm

14. **Dewhurst, S., Skrincosky, D., and van Loon, N.** Human herpesvirus 7. **Expert Reviews in Molecular Medicine**, 1997. *Full-text online at:* http://www-ermm.cbcu.cam.ac.uk/sdr/txt002sdr.htm

15. **Whetter, L., Ojukwu, I.,** Novembre, F., and **Dewhurst, S.** Pathogenesis of simian immunodeficiency virus infection. **J. Gen. Virol.** 80:1557-1568, 1999.

16. **Dewhurst, S., da Cruz, R.L.W,** and **Whetter, L.** Pathogenesis and treatment of HIV-1 infection: Y2K update. **Frontiers Biosci.** 5, d30-49, 2000. *Full text online at:* http://www.bioscience.org/2000/v5/d/dewhurst/fulltext.htm
Note: This review article is a revised and updated version of the previously published review of the same name (#12), which includes extensive new information and an additional author.

17. Caserta, M.T., Mock, D., and **Dewhurst, S**. Emerging Infections: Human herpesvirus 6. **Clin. Infect. Dis.** 33:829-33, 2001.

18. Perry, S.W., **Dewhurst, S.**, Bellizzi, M.J. and Gelbard, H.A. Conflicting effects of TNF-α in normal and diseased brain: intraneuronal receptor crosstalk as one mechanism for explaining the paradox. **J. Neurovirol.** 8:611-624, 2002.

19. **Dewhurst, S**. Various reprinted forms, including Biosafety guidelines and policies. In: *Medical Laboratory Management: Forms, Checklists and Guidelines*. Aspen Publishers, Gaithersburg, MD. 2003.
20. **Dewhurst, S**. Human herpesvirus type 6 and human herpesvirus type 7 infections of the central nervous system. Herpes. 2004 Jun;11 Suppl 2:105A-111A. *International Herpesvirus Management Foundation (IHMF) Monograph. See: http://www.ihmf.org/library/lib_mon.asp*
21. **Bradel-Tretheway, B., and Dewhurst S.** Molecular testing for HHV-6 infection. In: *Human Herpesvirus-6, 2nd Edition. Editors: Krueger, G.R.F., and Ablashi, D.V. (Part of Series, "Perspectives in Medical Virology"; Series Editor = Zuckerman, A.J.).* 2006.
22. **Santos, K. *, Duke, C. *, and Dewhurst, S.** HSV-1 amplicons as vaccine-delivery vectors. **Current Gene Ther.** 6:383-92, 2006. **: Co-First Authors.*
23. **Dewhurst, S.,** Maggirwar, S.B., Schifitto, G., Gendelman, H.E., and Gelbard, H.A. Glycogen synthase kinase 3-ß (GSK-3ß) as a therapeutic target in neuroAIDS. **J. Neuroimmune Pharm**. 2:93-96, 2007.
24. Gelbard, H.A., **Dewhurst, S**., Maggirwar, S.B., Kiebala, M., Polesskaya, O., and Gendleman, H.E. Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase. **Neurotherapeutics**, 7:392-398, 2010. PMCID: PMC2948545
25. Caserta, M.T., **Dewhurst S**. Dazed and confused by HHV-6. **Blood**, 117:5016-8, 2011 ("Inside Blood" article).
26. **Olsen, J.T., Easterhoff, D., Dewhurst, S**. Advances in HIV microbicide development. **Future Med. Chem**. 3:2101-16, 2011.
27. Ablashi, D., Agut, H., Alvarez-Lafuente, R., Clark, D.A., **Dewhurst, S.**, Diluca, D., Flamand, L., Frenkel, N., Gallo, R., Gompels, U.A., Höllsberg, P., Jacobson, S., Luppi, M., Lusso, P., Malnati, M., Medveczky, P., Mori, Y., Pellett, P.E., Pritchett, J.C., Yamanishi, K., Yoshikawa, T. Classification of HHV-6A and HHV-6B as distinct viruses. **Arch Virol.** 159:863-70, 2014. PMCID: In Process.
28. Mattiacio, J.L., **Brewer, M**., **Dewhurst, S.** Display of HIV-1 Envelope Protein on Lambda Phage Scaffold as a Vaccine Platform. **Methods Mol Biol.** 1581:245-253, 2017. PMID: 28374253
29. Sheik, D.A., **Dewhurst, S**., Yang, J. Natural Seminal Amyloids as Targets for Development of Synthetic Inhibitors of HIV Transmission. **Acc Chem Res.** 50:2159-2166, 2017. PMID: 28809479
30. Baas, T., **Dewhurst, S**., Peyré, S. Chapter 6 - Leadership and management for scientists. In: **BEST: Implementing Career Development Activities for Biomedical Research Trainees** (Eds.: Lara, L.I., Daniel, L., Chalkley, R.), p87-101, Academic Press, 2020.

Letters, Editorials, Short Articles and Other Contributions

1. Volsky, D.J., Wu, Y.T., Stevenson, M., **Dewhurst, S.,** Sinangil, F., Merino, F., Rodriques, L., and Godoy, G. Antibodies to HTLV-III/LAV in Venezuelan patients with acute malarial infections. **N. Engl. J. Med.** 314: 647, 1986.
2. Smith, D.M., **Dewhurst, S.,** Shepherd, S., Volsky, D.J., and Goldsmith, J.C. False positive EIA reactions for antibody to HTLV-III in a population of midwestern patients with congenital bleeding disorders. **Transfusion** 27:112, 1987.
3. **Dewhurst, S.** Poverty among U.S. children. **Science** 247:904, 1990.
4. Ablashi, D.V., Agut, H., Berneman, Z., Campadelli-Fiume, G., Carrigan, D., Ceccerini-Nelli, L., Chandran, B., Chou, S., Collandre, H., Cone, R., Dambaugh, T., **Dewhurst, S.,**

DiLuca, D., Foa-Tomasi, L., Fleckenstein, B., Frenkel, N., Gallo, R., Gompels, U., Hall, C., Jones, M., Lawrence, G., Martin, M., Montagnier, L., Neipel, F., Nicholas, J., Pellett, P., Razzaque, A., Torrelli, G., Thomson, B., Salahuddin, S., Wyatt, L., and Yamanishi, K. Human herpesvirus-6 strain groups: a nomenclature. **Arch. Virol.** 129:363-366, 1993.

5. **Dewhurst, S.** Web site reviews: Cornell Education Center & Protein Reviews on the Web. **ASM News** 65:503, 1999.
6. Buckley, G., Smith, S., DeCaro, J., Barnett, S., **Dewhurst, S**. Building community for deaf scientists. **Science** 355:255, 2017. PMID: 28104859

Other Contributions

URMC Blog posts, 2019-pres:

Topics include URMC research activities as well as ongoing impact of the COVID-19 pandemic. The two examples below were both in the top-10 most clicked articles on the URMC intranet in 2019.

1. The Loneliness of Grant Writing
   http://sites.mc.rochester.edu/faculty/top-stories/180820_research-roundup_loneliness-of-grant-writing
2. Values
   http://sites.mc.rochester.edu/faculty/top-stories/181017_research_roundup-values/

Contributions by Trainees/Supervised Personnel

1. **Sanchez, J.F.**, Sniderhan, L.F., Williamson, A.L., Fan, S., Chakraborty-Sett, S., Maggirwar, S.B. Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. **Mol Cell Biol.** 23:4649-62, 2003.
2. Martinez, C.V., Old, M.O., Kwock, D.K., Khan, S.S., Garcia, J.J., Chan, C.S., **Webster, R**., Falkovitz-Halpern, M.S., Maldonado, Y.A. Shedding of Sabin Poliovirus Type 3 containing the nt-472 U to C point mutation after administration of Oral Poliovirus Vaccine. **J. Infect Dis** 190: 409-16, 2004.
3. **Webster, R**., Johnson, R.P. Delineation of multiple subsets of Natural Killer cells in rhesus macaques. **Immunol.** 115:206-214, 2005.
4. Huang, J., Li, X., **Maguire, C.A.,** Hilf, R., Bambara, R.A., and Muyan, M. Binding of estrogen receptor beta to estrogen response element in situ is independent of estradiol and impaired by its amino terminal region. **Molecular Endocrinology** 19:2696-712, 2005.
5. Klenovsek, K., Weisel, F., Schneider, A., Appelt, U., Jonjic, S., Messerle, M., **Bradel-Tretheway, B**., Winkler, T.H.,and Mach, M. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. **Blood** 110:3472-9, 2007.
6. Kiebala, M., **Polesskaya, O.**, Yao, Z., Perry, S.W., Maggirwar, S.B. Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. **PLoS One** 5:e11875, 2010.
7. Perry SW, Barbieri J, Tong N, **Polesskaya O**, Pudasaini S, Stout A, Lu R, Kiebala M, Maggirwar SB, Gelbard HA. Human Immunodeficiency Virus-1 Tat Activates Calpain Proteases via the Ryanodine Receptor to Enhance Surface Dopamine Transporter Levels and Increase Transporter-Specific Uptake and Vmax. **J. Neurosci.** 30:14153-64, 2010.
8. Lin F, Roiland R, **Polesskaya O**, Chapman B, Johnson M, Brasch J, Chen DG, Mapstone M. Fatigability Disrupts Cognitive Processes' Regulation of Inflammatory Reactivity in Old

Age. **Am. J. Geriatr. Psychiatry** S1064-7481(13)00423-5. doi: 10.1016/j.jagp.2013.12.003, 2013

G. Patents

Issued Patents

1. Alpha..Nu..Beta.3 integrin-binding polypeptide monobodies and their use. **US Patent # 7,556,925; Issued: July 7, 2009.** Inventors: S. Koide, S. Dewhurst, A. Koide, J. Richards, M. Miller.
2. Helper virus-free herpesvirus amplicon particles and uses thereof. **US Patent # 8,119,118; Issued: February 21, 2012.** Inventors: H. Federoff, W.J. Bowers, J.G. Frelinger, R.A. Willis, T.D. Evans, S. Dewhurst, K.A. Tolba, J.D. Rosenblatt.
3. Modified phage for displaying post-translationally modified proteins and uses thereof. **US Patent #: US 8,754,015; Issued: Jun. 17, 2014.** Inventors: S. Dewhurst, J. Treanor.
4. Bicyclic heteroaryl kinase inhibitors and methods of use. **US Patent #: US 8,846,909; Issued: Sept. 30, 2014.** Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, T. Wiemann, S.B. Ravula, C.J. Loweth
5. Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors. **US Patent #: US 8,877,772 B2**; **Issued: Nov. 4, 2014.** Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, C. Loweth, T. Wiemann
6. Antigenic mimics of discontinous epitopes of pathogen recognized by broadly neutralizing antibodies. **US Patent #: US 8,961,977**; **Issued: Feb. 24, 2015.** Inventors: M.A. Sullivan, S. Dewhurst.
7. Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors. **US Patent #: US 9,181,247**; **Issued: Nov. 10, 2015.** Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, C. Loweth, T. Wiemann
8. Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors. **US Patent #: US 9,814,704**; **Issued: Nov. 14, 2017.** Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, C. Loweth, T. Wiemann
9. Attenuated influenza vaccines and uses thereof. **US Patent #: US 9,878,032**; **Issued: January 30, 2018.** Inventors: A. Cox, S. Dewhurst, J. Treanor, B. Kim
10. Attenuated influenza vaccines and uses thereof. **US Patent #: 10,323,231. Issued: June 18, 2019.** Inventors: A. Cox, S. Dewhurst, J. Treanor.
11. Mixed lineage kinase inhibitors for HIV/AIDS therapies. **US Patent #: 10,485,800. Issued: November 26, 2019.** Inventors: H.A. Gelbard, S. Dewhurst, H.E. Gendelman.
12. Methods and compositions related to increasing the fidelity of influenza A virus for vaccine development. **US Patent #: 10,500,268. Issued: December 10, 2019.** Inventors: A. Cox, S. Dewhurst.

Patent Applications

1. **Application** #: 20030027322. Helper virus-free herpesvirus amplicon particles and uses thereof. Inventors: H.J. Federoff, W.J. Bowers, J.G. Frelinger, R.A. Willis, T.D. Evans, S. Dewhurst, Tolba, K.A., Rosenblatt, J.D. Filed, 2003.
2. **Application #:** 20050112555. Cytidine Deaminase Activators, Deoxycytidine Deaminase Activators, Vif Antagonists, and Methods of Screening for Molecules Thereof. Inventors: H.C. Smith, J.E. Wedekind, M.P. Sowden, S. Dewhurst, B. Kim. Filed, 2005.

3. **Application #:** 20050287648. Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof. Inventors: H.C. Smith, M.P. Sowden, S. Dewhurst, B. Kim. Filed, 2005.
4. **Application #:** 20060204477. Helper virus-free herpesvirus amplicon particles and uses thereof. US Patent # 8,119,118; Issued: February 21, 2012. Inventors: H. Federoff, W.J. Bowers, J.G. Frelinger, R.A. Willis, T.D. Evans, S. Dewhurst, K.A. Tolba, J.D. Rosenblatt. Filed, 2005. **Patent issued, 2012.**
5. **Application #:** 2007011796. Alpha..Nu..Beta.3 integrin-binding polypeptide monobodies and their use. Inventors: S. Koide, S. Dewhurst, A. Koide, J. Richards, M. Miller. Filed, 2007. **Patent issued, 2009.**
6. **Application #:** 20080269161. Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease. Inventors: S. Perry, J.P. Norman, S. Dewhurst, H.A. Gelbard. Filed, 2008.
7. **Application #:** 20080305119. Modified Bacteriophage Vectors and Uses Thereof. Inventors: S. Dewhurst, C.N. Zanghi, J.R. Gunzler. Filed, 2008.
8. **Application #:** 20090081318. Treatment of NeuroAIDS Using Inhibitors of Glycogen Synthase Kinase (GSK)-3. Inventors: H.A. Gelbard, S.B. Maggirwar, S. Dewhurst, G. Schifitto. Filed, 2009.
9. **Application #:** 20090181889. Compositions and Methods for Detection and Treatment of Human Herpevirus (HHV)-6. Inventors: S. Dewhurst, B. Bradel-Tretheway, Z. Zhen. Filed, 2009.
10. **Application #:** 20100160174. Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds and Uses Thereof. Inventors: H.C. Smith, M.P. Sowden, S. Dewhurst, B. Kim, J. Wedekind. Filed, 2010.
11. **Application #:** 20100284967. Modified phage for displaying post-translationally modified proteins and uses thereof. Inventors: S. Dewhurst, J. Treanor. **Patent issued, 2014.**
12. **Application #:** 20100316609. Conditionally Replicating Viruses for Cancer Therapy. Inventors: S. Dewhurst, B. Kim. Filed, 2010.
13. **Application #:** 20110081317. Enhancing Gene Transfer. Inventors: S. Dewhurst, C.N. Zanghi, K. Volcy, J.J. Schlesinger. Filed, 2011.
14. **Application #:** 20110171257. Herpes Simplex Virus Amplicon Vectors Derived from Primary Isolates. Inventors: S. Dewhurst, W.J. Bowers, H.J. Federoff, M.C. Keefer, J.G. Frelinger. Filed, 2011.
15. **Application #:** 20120053175. MLK Inhibitors and Methods of Use. Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, C. Loweth, T. Wiemann. Filed, 2012. **Patent issued, 2014.**
16. **Application #:** 20130039927. Antigenic mimics of discontinous epitopes of pathogen recognized by broadly neutralizing antibodies. Inventors: M.A. Sullivan, S. Dewhurst. Filed, 2013. **Patent issued, 2015.**
17. **Application #:** 20130157924. Reducing Transmission of Sexually Transmitted Infections. Inventors: J. Yang (UCSD); S. Dewhurst, J. Olsen, B. Nilsson (UR). Filed, 2013.
18. **Application #:** 20130203755. Bicyclic heteroaryl kinase inhibitors and methods of use. Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, T. Wiemann, S.B. Ravula, C.J. Loweth. Filed, 2013. **Patent issued, 2014.**

19. **Application #:** 20140323420. Reducing Transmission of Sexually Transmitted Infections. Inventors: S. Dewhurst, D. Easterhoff, B. Nilsson, J. Dimaio, A. Smrcka, J. Yang (UCSD), C. Capule (UCSD). Filed, 2014.
20. **Application #:** 20150105401. MLK Inhibitors and Methods of Use. Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, C. Loweth, T. Wiemann. Filed, 2015. **Patent issued, 2017.**
21. **Application #:** 20150224187. Attenuated influenza vaccines and uses thereof. Inventors: A. Cox, S. Dewhurst, J. Treanor, B. Kim. Filed, 2015. **Patent issued, 2018**.
22. **Application #:** 20150297587. Mixed lineage kinase inhibitors for HIV/AIDS therapies. Inventors: H.A. Gelbard, S. Dewhurst, H.E. Gendelman (U-Nebraska). Filed, 2015.
23. **Application #:** 20160024087. MLK Inhibitors and Methods of Use. Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, C. Loweth, T. Wiemann. Filed, 2015. **Patent issued, 2017.**
24. **Application #:** 20160136260. Attenuated influenza vaccines and uses thereof. Inventors: A. Cox, S. Dewhurst, J. Treanor, B. Kim. Filed, 2016. **Patent issued, 2018**.
25. **Application #:** 20160317509. MLK Inhibitors and Methods of Use. Inventors: H.A. Gelbard, S. Dewhurst, V.S. Goodfellow, C. Loweth, T. Wiemann. Filed, 2016.
26. **Application #:** 20180223261. Attenuated Influenza Vaccines and Uses Thereof. Inventors: A. Cox, S. Dewhurst, J. Treanor. Filed, 2018. **Patent issued, 2018**.
27. **Application #:** 20190000958. Methods and Compositions Related to Increasing the Fidelity of Influenza A Virus for Vaccine Development. Inventors: A. Cox, S. Dewhurst. Filed, 2019. **Patent issued, 2019**.